Rabies, a global threat: taking science a step forward by Smith, Mylissia Rachelle
  
 

























Department of Diagnostic Medicine and Pathobiology 


















           MYLISSIA R SMITH 








Rabies is the most deadly disease on earth and has a 99.9% human fatality rate.  Rabies 
kills 61,000 humans annually and results in an economic burden of $124 billion USD annually.  
Each day 3.3 million people live with the risk of rabies.  It is estimated that 95% of human rabies 
cases are a result of coming in contact with an infected canine, majority of these cases being 
children 15 years and younger.  It is estimated that 1 person every 8 minutes dies of rabies.  
Rabies is a highly neurotropic disease which attacks the brain and central nervous system.  Once 
clinical symptoms are presented, death is invariably the outcome as no cure exists for rabies.  
Rabies is 100% preventable in humans by proper wound management and proper administration 
of prophylaxis.  Rabies can be adequately controlled in animal populations by contraception and 
animal rabies vaccine efforts.  Whilst it is known that rabies can be prevented in humans and 
controlled in animal populations, further scientific efforts are still warranted to fully understand 
this deadly virus so that a cure can one day be discovered.  As human and animal populations 
continue to grow, so does the cost and burden of this horrific disease.  As a result, the importance 
of prophylaxis and passive immunity are critical in the event of medically managing an 
exposure, and preventing exposures.  The World Health Organization has defined global 
recommendations for individuals and animals who have received prophylaxis to be adequately 
protected.  Measuring this protection is performed using a variety of approved testing 
methodologies, virus-neutralizing assays and antigen-binding assays.  Whilst the WHO 
recommendations were defined from clinical studies performed with virus-neutralizing assays, 
the assumption that these recommendations are suitable for the antigen-binding assays is 
inaccurate.  The testing methodologies, virus-neutralization and antigen-binding, share 
similarities, as they are measuring an immune response to the rabies virus.  However; enough 
differing characteristics are presented such that exact comparisons cannot be made.  Establishing 
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CHAPTER 1 – INTRODUCTION TO RABIES 
“Rabies, one of the world’s deadliest diseases, impacts 5 billion people, causing tens of 
thousands of deaths every year” (Global Alliance for Rabies Control, 2013). Rabies is a global 
threat and can be found on every continent, excluding Antarctica (World Health Organization, 
2014).  Although rabies serves as a prominent global public health threat, rabies is a preventable 
disease in humans by means of proper vaccination and education.   
 
 History of Rabies: 
Rabies, a viral disease of mammals, is one of the oldest infectious diseases known to man 
and can be traced back more than 4000 years (Rupprecht, 2011).  In looking through historical 
records, the first documentation of rabies occurred in the city of Eshnunna in 2300 BC where it 
was written, ‘If a dog is mad and the authorities have brought the fact to the knowledge of its 
owner; if he does not keep it in, and it bites a man and causes his death, then the owner shall pay 
two thirds of a mine of silver’ (Baer, 2007, pg. 1).  One of the first documentations of a canine 
rabies case comes from a Greek philosopher named Democritus in 500 BC in which descriptions 
of a case of canine rabies was recorded in his papers, (“A short history of rabies,” 2013).  The 
disease of rabies is also written in early poems and books; In 800 – 700 BC Homer writes about 
the disease in a poem titled The Iliad (“A short history of rabies,” 2013) and in 400 BC Aristotle 
depicts the disease in a book titled the Natural History of Animals (Hernandez, 2009).  At the 
time of 400 BC, Greeks identified two gods for the prevention and cure of rabies.  The god to 
prevent the disease was known as Arisaeus and the god said to cure rabies was known as Artemis 
(“A short history of rabies,” 2013).  The word “rabies” stems from the Latin word rabere which 
is defined as rave or rage.  It is believed that the word rabere is rooted in the Sanskrit word 
rabhas which is defined as doing violence (“A short history of rabies,” 2013).  By 001 – 100 
AD, rabies spread across the Roman Empire and in 1271, the first large rabies outbreak is 
recorded, 30 people die from rabies in Germany due to an invasion of rabid wolves (“A short 
history of rabies,” 2013).  In the 1400s, rabies spread across Spain, and in the 1700s, rabies made 
its way through Europe.  In 1703, the first case of rabies was noted in the Americas by a priest in 
Mexico, and in 1953, the first case of bat rabies was recorded in the United States by the Centers 
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for Disease Control and Prevention (“A short history of rabies,” 2013). 
 As long as rabies has been known to man, myths about the cause, transmission and 
‘cures’ for the disease have played an instrumental role in society and have impacted the health 
of animals and man.  Some myths throughout history include the belief that witches cause rabies 
by spells and evil spirits, ambient temperatures cause rabies, or that a worm located in the base 
of the tongue of a canine caused rabies.  It was believed that if this worm was cut and removed 
from the tongue, then the canine would be cured of the disease. Cauterization of wounds was 
also believed to cure the disease, as was having individuals physically suck the wound to remove 
the poisons.  The same aforementioned worm was also believed to have magical powers to 
prevent rabies when injected.  Other preventions for rabies included individuals eating cocks 
brains and consuming salted flesh from a rabid dog.  Consuming maggots from a rabid dog were 
also believed to be a remedy (Baer, 2007).  Furthermore, history reflects the belief of placing 
animal hair over the wound would cure the disease as would having the child that was bitten by a 
rabid animal eat the raw heart or liver of the animal that bit them (Baer, 2007).  Herbal remedies 
thought to cure rabies throughout history included utilizing the Angelica archangelica plant in a 
powered form as an external plaster.  Ballota nigra plant leaves were beaten with salt and then 
applied to the wound.  The Pelteriga canina plant was utilized whole with black pepper and then 
placed in milk after which four doses were given to the individual or animal.  The Julgans regia 
plant leaves would be placed in wine along with onions, honey and salt to use internally for the 
‘treatment’ of rabies (Baer, 2007).  To prevent coming in contact with a rabid animal, individuals 
were known to carry weasel tails as well as place the heart or tongue of a rabid dog in one’s shoe 
(Baer, 2007).  Prayer and divine intervention was another method utilized to prevent and ‘cure’ 
rabies throughout history.  An example of this stems from the early centuries when Christians 
would travel to visit a well-known bishop by the name of St. Hubert in Europe.   St. Hubert 
became known as the patron against rabies when it was believed that he ‘cured’ an individual 
with the disease by stating the words ‘May the Lord Jesus heal you’ as the individual believed to 
have rabies approached him (Baer, 2007).  History reflects that this individual then walked away 
cured of the disease.  This act resulted in visitations to St. Hubert from individuals around the 
world who believed they had the disease seeking out a cure.  Individuals who owned canines 
suspected of having the disease from various parts of the world also visited St. Hubert to cure 
their canines of the ‘madness’.  St. Hubert utilized a metal rod in the form of a nail, known as St. 
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Hubert’s Key to cauterize the wounds of animals and humans that were bitten (St. Hubert Club, 
2014).  Figure 1.1.  The idea of heating of the nail would allow for the disease to be killed once 
the nail was placed into the wound (they glyptodont, 2014).   The role of St. Hubert led to revolt 
and the speaking out against superstitions in religion (“A short history of rabies,” 2013).  Myths 
about rabies continue to play an instrumental role in societies around the world.  Religious and 
cultural beliefs are highly influential in rabies prevention and ‘treatment’.  Ironically, it is also 
currently believed that rabies is a rare disease which is not widespread around the world, whilst 
some share the belief that “nothing can be done to make an impact toward rabies elimination” 
(Rupprecht, 2011).   
 Although individuals were significantly influenced by the aforementioned myths for 
rabies cures and preventions, not all individuals were convinced of such beliefs.  “Even in the 1
st
 
century, the optimism about curing rabies was not shared by Scribonius Largus, who affirms that 
a rabid patient is never cured…” (Baer, 2007, pg. 2). While the source of rabies was questioned 
throughout history, it wasn’t until the 1
st
 century AD that the transmission of the disease from 
wild animals was recognized.  In the New World, the first description of rabies transmission 
from a wild animal to man was documented in the early 16
th
 century as a gentleman was dying 
from bites that were received from vampire bats.  From the 1
st
 century AD comes the ‘first 
recorded attempt at defining the cause of rabies and prescribing treatments, as it was written in 
the words of a poem titled ‘On Hunting’ by author Grattius Faliscus (Baer, 2007).  And in 1804 
an individual named Zinke first demonstrated that rabies was transmitted through saliva.  Zinke 
placed the saliva of a rabid dog onto an incision of another dog.  The second dog began to fall ill 
on the seventh day, and by the tenth day obvious symptoms of the disease were present.  This 
demonstration resulted in many articles being written about the pathogenesis (development of the 
disease) and ‘treatment’ of rabies throughout the 19
th
 century.  In 1879 Galitier proved that the 
disease could affect rabbits through an injection or by a bite of a rabid animal.  Galitier’s 
experiments and studies were followed by French chemist and microbiologist Louise Pasteur 
who discovered that rabies is produced in the brain and spinal cord.  Figure 1.2. Pasteur also 
discovered that if rabies was injected directly into the brain, then paralysis and death were 
inevitably the result.  Pasteur’s work proved that the brain is the fundamental organ in the 
pathogenesis of the disease.  Pasteur then proceeded to develop the first vaccine against rabies.  
“The initial vaccination consisted of a series of inoculations prepared from dried spinal cord 
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tissues from rabbits that had died from rabies, the 13
th
 dose consisting of the most virulent 
preparation” (Hooper, Roy, Barkhouse, Li, Kean, 2011, pg. 60).  Pasteur’s vaccine was then 
successfully utilized on fifty canines.  In 1885 Pasteur took a step forward and utilized his 
vaccine on a young boy the day after the boy had been repeatedly bitten by a rabid canine.  After 
several injections of the vaccine developed by Pasteur, the boy survived.     
 In 1921, thirty-five years following the work of Louise Pasteur, the first national program 
for canine vaccinations occurred in Japan.  These efforts set a model for other countries began to 
follow suit.  The result of such endeavors lead to the World Health Organization (WHO) to set 
global recommendations that all canines should be vaccinated annually or every three years as 
approved by current vaccine labels.  The WHO is an organization that “is the directing and 
coordinating authority for health within the United Nations system. It is responsible for 
providing leadership on global health matters, shaping the health research agenda, setting norms 
and standards, articulating evidence-based policy options, providing technical support to 
countries and monitoring and assessing health trends” (WHO, 2014).  The WHO continues to 
play a leading global role in the efforts towards rabies education and elimination on a global 
scale to this day.    
 
                            Figure 1.1           Figure 1.2 
                  
 
 
Photograph of St. Hubert’s Key, 
utilized to cauterize wounds to ‘cure’ 
rabies (The Glyptodont, 2014). 
Photograph of Dr. Louis Pasteur, 
French Chemist whom developed the 
first rabies vaccine (Bio.True Story, 
2014). 
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 Rabies Virus Introduction and Pathogenesis 
 As a result of scientific advancements through time it is known that rabies is not the 
result of witches spells, ambient air or worms of the canine tongue as previously discussed.  
Rabies is an acute virus that affects the central nervous system and is almost unvaryingly fatal.  
Rabies is a zoonotic disease that can be transmitted from animals to humans and is primarily 
spread through the bite of an infected mammal through saliva.  Other routes of transmission 
include aerosol transmission, mucosal contact (i.e., mouth, nose, eyes) licking of broken skin, 
transplantations of organs and corneas, and penetration of the skin from a scratch where bleeding 
occurs.  It is important to note that non-bite transmissions rarely cause rabies in humans 
(Rupprecht, 1996) and that human to human transmission, aside from transplantations, has never 
been documented (International Travel and Health, 2014).  In the United States, 5 human rabies 
cases out of 154 were a result of non-bite incidences from 1950 through 1980 (Rupprecht, 1996).   
Two cases resulted from laboratory-acquired infections and two cases were cave explorers, all of 
which were undoubtedly exposed to high concentrations of rabies virus (Rupprecht, 1996).  The 
fifth human rabies case resulted from a transplant of a cornea which was received from a patient 
that was dying from an unsuspecting case of rabies encephalitis (Rupprecht, 1996).    
 The rabies virus is highly neurotropic (affects or attacks the nervous system).  Once the 
virus enters an individual it, may replicate within the tissue (at or near the entry site) and remain 
sequestered (segregated or secluded) during incubation.  The virus will then enter the peripheral 
nerves and travel to the central nervous system where it will continue to replicate, then travel out 
to the organs, including the salivary glands.  The salivary glands are the primary exit portal in 
which the virus is excreted and passed on to other hosts.  In humans, five general clinical stages 
for rabies are recognized: incubation, prodromal stage, acute neurologic phase, coma and death 
or very rarely, recovery (Rupprecht, 2011).  In humans, the incubation period can be anywhere 
from ten days to ten years whilst the average incubation is three to six weeks (Rupprecht, 2014).  
The prodromal stage consists of nonspecific signs, such as headache, fever, nausea, sore throat, 
anxiety, increased sensitivity to noise and light, hallucinations, fear of air (aerophobia), fear of 
water (hydrophobia), etc.  Additional abnormal signs can also occur during the prodromal stage, 
such as increased libido, nightmares, depression, insomnia, etc.  The acute neurologic phase is 
where signs of dysfunction within the central nervous system become apparent.  During the onset 
of the acute neurologic phase, encephalitis (inflammation of the brain) occurs in which the 
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central nervous system becomes dominated by the virus.  At this time, the disease is then 
classified into one of two forms: hyperactivity, known as furious rabies, or paralysis known as 
paralytic rabies (also known as dumb rabies).  “At the end of the acute neurologic phase, periods 
of rapid, irregular breathing may begin; paralysis and coma soon follow.  Respiratory arrest may 
occur thereafter, unless the patient is receiving ventilator assistance, which may prolong survival 
for days, weeks, or longer, with death due to other complications” (Rupprecht, 1996).  While 
ventilation assistance can prolong the clinical signs of rabies, it will rarely affect the outcome of 
the disease itself.  Once the onset of symptoms occurs, rabies is nearly one hundred percent fatal.  
“Rabies has one of the highest case-fatality ratios of any infectious disease” (MMWR, 2011).   
 The rabies virus is best described as an enveloped, rod or bullet shape (bacilliform) in its 
appearance (morphology).  Figure 1.3.  One end of the virus particle (also known as virion) 




    
The origin of the virus, is that of the Mononegavirales order (WHO, 2012).  The 
Mononegavirales order contains numerous viruses, all of which cause harmful diseases in 
humans.  Viruses in the Mononegavirales order are single-stranded, nonsegmented, negative-
stranded ribonucleic acid (RNA) genomes (CDC, 2013).  Within the Mononegavirales order, the 
bullet-shaped viruses are classified in the Rhabdovirdae family which consists of 12 genus 
species (WHO, 2012).  Rabies is part of the Lyssavirus genus (WHO, 2012).  To better 
understand how these names were identified, the Greek words rhabdos means ‘rod’ and lyssa 
Photograph of the rabies virus.  Negatively stained 
rabies (Rhabdovirus) as seen through an electron 
microscope. Notice the bullet shape of the virus (A). 
See the "bee hive" like striations of the RNP (B). Notice 
the glycoprotein spikes in the outer member bilayer (C) 
(Centers for Disease Control and Prevention, 2014) 
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means ‘rage’ (Wunner, 2007).  The rabies virion, is approximately 180 nanometers (nm) long 
and 75 nm wide (CDC, 2013).  Rabies is an RNA virus, as previously mentioned, in which the 
virus particle (virion) encodes five different proteins.  These proteins are nucleoprotein (N), 
phosphoprotein (P), matrix protein (M), glycoprotein (G) and polymerase (L) (CDC, 2013).  The 
basic structure of the rabies virus is depicted below.  Figure 1.4.  Relative size and order of the 












Rabies virion are rod or bullet-shape with spike-like glycoprotein covering the surface.  
The ribonucleoprotein is composed of RNA encased in nucleoprotein (Centers for 
Disease Control and Prevention, 2014) 
The rabies virus encodes five proteins; (N) nucleoprotein, ( P) phosphoprotein, (M) 
matrix protein, (G) glycoprotein and (L) polymerase.  The order and the size of the 
proteins is imperative as this makes up the virus (Centers for Disease Control and 
Prevention, 2014).     
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 It is important to note that the location of these five proteins and the RNA determine the 
structure of the rabies virus.  Whilst this paper will not go into detail in describing the replication 
and strategies of the rabies virus, it is important to understand the virus and how it affects 
individuals and continues to survive and infect new individuals. 
 All rhabdoviruses, including the rabies virus, include two major structural components.  
These two components are a helical ribonucleoprotein core (RNP) and a surrounding envelope.  
The L and the P protein are associated with the RNP as they aid in the replication process.  The 
G protein which is spiked, as depicted in Figure 1.4, is located on the surface of the virion as it is 
used to physically attach to the host cell membranes (Rupprecht, 1996).  The M protein is 
associated with the RNP and the envelope which plays a key role in virion assembly and egress 
(Okumura, Harty, 2011).  The M protein is also known to play an important role in giving the 
virion its bullet-shaped appearance (Wunner 2007).  Without going into great detail, the N 
protein encapsidates (encloses) the genomic and antigenomic RNA.  The genomic includes an 
individual’s full DNA sequences (Web definitions, 2014).   
 The life cycle of a rabies infection begins by the attachment of the virion to the surface of 
the cell membranes in which penetration of the virion is initiated.  It is important to note that 
most often the virion attaches to a receptor molecule that will permit the virion to enter the 
susceptible cell membranes (Wunner, 2007).  The life cycle of the rabies infection can be divided 
into three phases.  The first phase, as discussed, includes the attachment of the virion to 
susceptible cell membranes by which the virion then enters the host cell.  This phase initiates the 
infection process.  This phase of the life cycle is considered to be the most difficult phase 
(Wunner, 2007).  The second phase of the life cycle includes replication of the virion in the host 
cell.  The third phase consists of final replication of new virions which are then released 
(budding) from the cell to attach to new host cells, starting the life cycle process over again.  
Figure 1.6.  
 “Rabies is a fatal disease.  Clinical management of rabies patients should include 
adequate sedation and care in an appropriate medical facility with suitable emotional and 
physical support” (WHO, 2012).  If intensive care is not provided, death normally occurs within 
two weeks of the onset of clinical signs, although typically, death results in seven to ten days 
after the first clinical sign (WHO, 2012).  It is important to note that there currently is no cure for 
rabies after the onset of clinical symptoms.  An experimental approach, known as the Milwaukee 
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protocol, has been utilized around the world on approximately 40 patients.  This protocol 
involves inducing the patient into a coma state and administering antiviral drug treatment.  Out 
of the 40 patients around the world, there are 4 reported survivors (Centers for Disease Control 
and Prevention, 2013).  “Despite these observations, rabies must still be considered 100% fatal 
for practical purposes, and preventive measures remain the only way to guarantee survival after a 
bite by a rabid animal” (Centers for Disease Control and Prevention, 2013, pg. 1).   
   






 As aforementioned, rabies is part of the Rhabdoviridae family and is caused by a 
Lyssavirus which is an acute progressive encephalitic disease that can affect all mammals.  It has 
also been discussed that “rabies has one of the highest case-fatality ratios of any infectious 
disease” (Compendium of Animal Rabies Prevention and Control, 2011).  Rabies is a difficult 
Steps of the life cycle of the rabies virus/virion for infection and replication in a 
susceptible host cell (Centers for Disease Control and Prevention, 2014).  
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disease to diagnose as it mimics the signs of other diseases and is often misdiagnosed in the early 
stages when clinical signs first appear (World Organization for Animal Health, 2009).  Although 
a variety of testing methods exist, it is important to note that a negative test does not rule out a 
rabies infection.     
 In animals (all mammals excluding humans) rabies can be diagnosed, however, the 
animal must first be euthanized (put to death) as tissues from the brain must be collected and 
tested.  Two tissues from the brain are required for testing and in order to successfully rule out a 
rabies diagnosis, the cerebellum and the brain stem must be test negative.  Brain tissue is 
required as the rabies virus resides in the nervous tissue and not blood as other viruses (Centers 
for Disease Control and Prevention, 2014).  The testing method utilized is the Direct Fluorescent 
Antibody test known as the DFA test.  While other testing methods exist, the DFA test is the 
gold standard for rabies diagnosis and must be performed according to standard protocol 
(Compendium of Animal Rabies Prevention and Control, 2011).  The DFA test utilizes 
antibodies that attach to the rabies virus (antigen) in the brain samples if the animal is positive 
for rabies.  When the animal is positive for rabies the samples will show a green-apple 
fluorescent color when viewed under a fluorescent microscope.  Figure 1.7.  This green-apple 
fluorescent will not be viewed for a negative sample.  Figure 1.8.  While the DFA test and other 
methodologies are beneficial in diagnosing rabies, it has been proven through public health 
surveillance and pathogenic studies that euthanizing an animal is not always necessary.  For 
animals that have a low probability of being rabid after biting an individual, the animal may be 
quarantined for 10 days to rule out rabies.  If the animal survives on and after the 10
th
 day than 
the rabies virus was not present in the saliva at the time of the bite.  This quarantine is effective 
as the salivary gland is an exit route and the animal will not survive the virus longer than 10 days 
once the virus is shedding in the saliva (Compendium of Animal Rabies Prevention and Control, 
2011).  For humans, a test does not exist for diagnosing rabies infection prior to the onset of 
clinical disease, and unless the rabies-specific signs of hydrophobia or aerophobia are present, 
the clinical diagnosis may be difficult (World Health Organization, 2013).  Once clinical 
symptoms are present, several tests are available as no single test is sufficient in diagnosing 
human rabies ante-mortem (before death).  Ante-mortem diagnosis includes detecting the antigen 
or nucleic acids of the rabies virus or by virus isolation.          
                   
    11 
 
                      Figure 1.7                   Figure 1.8 





    Samples utilized to detect rabies from humans include saliva, corneal impressions, eye wash 
fluid, central spinal fluid (CSF), tears, and skin biopsies (nuchal).  The nuchal biopsies are taken 
from the nape of the neck as the rabies virus is found in cutaneous nerves, which are located at 
the base of the hair follicle (World Organization for Animal Health, 2009). Serum may also be 
tested to look for antibody production against the rabies virus.  Antibody production is also 
tested for when testing the CSF.  It is important to note that antibody production in the CSF can 
result from individuals that have previously been vaccinated against rabies.  It is also noteworthy 
that antibody response from a true rabies infection occurs in the late stages of the illness and the 
individual may die prior to this occurrence, resulting in a negative CSF test for circulating 
antibodies at the time of death.  These samples may also be utilized for post-mortem (after death) 
diagnosis in humans along with samples of the brain from the infected individual.  As a result, 
“postmortem diagnosis is usually by immunofluorescence to detect viral antigens in the brain” 
(WHO, 2013, pg. 3).   
  
DFA test viewed through a fluorescent 
microscope that is positive for rabies, 
(Centers for Disease Control and 
Prevention, 2014). 
DFA test viewed through a fluorescent 
microscope that is negative for rabies, 
(Centers for Disease Control and 
Prevention, 2014). 
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 Rabies Vaccine, Prophylaxis and Immunoglobulin 
   Several scientific and technological advancements have progressed since following the 
days of Louis Pasteur when the first rabies vaccine was developed in the 1880s.  Injectable 
animal rabies vaccine is currently approved for dogs, cats, ferrets, horses, sheep and cows.  The 
vaccines provide a variation of duration of immunity from 1 to 4 years (Compendium of Animal 
Rabies Prevention and Control, 2011).  In reference to domesticated animals, local governments 
are tasked with ensuring that effective vaccine programs are maintained.  Animal vaccines may 
be administered intramuscularly (in the muscle) or subcutaneous (under the skin).  
 Controlling rabies in wildlife is extremely difficult (Compendium of Animal Rabies 
Prevention and Control, 2011); however, the vaccination of free ranging wildlife or selected 
wildlife populations can be beneficial.  The oral rabies vaccine (ORV) was developed and 
designed to vaccinate certain wildlife species in the form of a sachet.  Figure 1.9.  The sachets 
are approximately the size of a matchbox and along with the vaccine the sachet can include 
fishmeal to attract certain animal species.  Figure 1.10.  The sachets are distributed in the 
animal’s environment by air and ground personnel.  Once the animal finds and bites into the 
sachet the animal then swallows the vaccine and is then vaccinated for rabies.  ORVs have been 
utilized in Europe since 1980, Canada since 1985 and the United States since 1990 (United 
States Department of Agriculture, 2012).    
ORVs have been successfully utilized to vaccinate raccoons, foxes, and coyotes in the United 
States.  The attempt to successfully vaccinate skunks with ORVs in the United States was 
attempted in the state of Texas during the routine ORV baiting in February 2014 (Forsyth, 2014).   
It is important to note that translocation of wildlife has made a significant impact in the spread of 
rabies.  As a result, the translocation of known rabies carrier species should be prohibited 
(Compendium of Animal Rabies Prevention and Control, 2011).  In respect to human rabies 
vaccines (prophylaxis), two areas of emphasis exists 1) pre-exposure prophylaxis and 2) post-
exposure prophylaxis.  Pre-exposure prophylaxis is aimed at vaccinating individuals that have a 
risk of being exposed to the rabies virus.  Pre-exposure prophylaxis is used as a preventive 
measure.  Individuals in this category include veterinarians, individuals traveling to an area with 
increased risks to  rabies (endemic), animal control officers, wildlife officers or laboratory 
personnel working with the rabies virus (WHO, 2014).                 
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                       Figure 1.9          Figure 1.10 





  Individuals in this group are considered high risk or continuous.  Pre-exposure 
prophylaxis should be considered for all individuals that consistently have the potential to be 
exposed to the rabies virus or have frequent potential contact with animals that can carry the 
rabies virus.  These individuals are considered moderate and low risk or frequent and infrequent.  
Table 1.1.   Pre-exposure prophylaxis consist of three doses of vaccine administered 
intramuscularly on day 0 (day of first vaccine), 7 and 21 or 28 (Centers for Disease Control and 







Photograph of coated sachet baits 
containing rabies vaccine only utilized for 
ORVs, (United States Department of 
Agriculture, 2012). 
Photograph of ORV baits containing 
fishmeal and rabies vaccine, (United 
States Department of Agriculture, 2012).    










Nature of Risk Typical Population Pre-exposure 
Recommendations 
Continuous Virus present continuously, 
often in high concentrations. 
Specific exposures likely to 
go unrecognized. Bite, 
nonbite, or aerosol exposure. 
Rabies research laboratory workers; 
rabies biologics production workers. 
Primary course. Serologic 
testing every 6 months; booster 
vaccination if antibody titer is 
below acceptable level. 
Frequent Exposure usually episodic, 
with source recognized, but 
exposure also might be 
unrecognized. Bite, nonbite, 
or aerosol exposure. 
Rabies diagnostic lab workers, 
spelunkers, veterinarians and staff, and 
animal-control and wildlife workers in 
rabies-enzootic areas. All persons who 
frequently handle bats. 
Primary course. Serologic 
testing every 2 years; booster 
vaccination if antibody titer is 
below acceptable level. 
Infrequent Exposure nearly always 
episodic with source 
recognized. Bite or nonbite 
exposure. 
Veterinarians and terrestrial animal-
control workers in areas where rabies is 
uncommon to rare. Veterinary students. 
Travelers visiting areas where rabies is 
enzootic and immediate access to 
appropriate medical care including 
biologics is limited. 
Primary course. No serologic 




Exposure always episodic 
with source recognized. Bite 
or nonbite exposure. 
U.S. population at large, including 
persons in rabies-epizootic areas. 
No vaccination necessary. 
Rabies Post-exposure Prophylaxis Guide 
Type of vaccination Route Regimen 
Primary Intramuscular Human diploid cell vaccine (HDCV) or purified 
chick embryo cell vaccine (PCECV); 1.0 mL 
(deltoid area), one each on  
days 0,* 3, 7, and 14 
Booster† Intramuscular HDCV or PCECV; 1.0 mL (deltoid area), day 0 
and 3 
*Day 0 is the day the first dose of vaccine is administered. 
†Persons in the continuous-risk category should have a serum sample tested for rabies virus neutralizing antibody every 6 months, and persons in 
the frequent-risk category should be tested every 2 years.  An intramuscular booster dose of vaccine should be administered if the serum t iter falls 
to maintain a value of at least complete neutralization at a 1:5 serum dilution by Rapid Fluorescent Focus Inhibition Test. 
Rabies Pre-exposure Prophylaxis Guide, (Centers for Disease Control and Prevention, 2014). 
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Post-exposure prophylaxis is aimed at vaccinating individuals that have possibly been 
exposed to the rabies virus.  ‘Have possibly’ been exposed is stated as individuals may not be 
aware they have been exposed or bitten.  An example is when a bat is found in the same area 
such as; a bedroom or tent, of an infant, adult or child (includes intoxicated or mentally disabled 
individuals).  Bats have small sharp teeth and often times the bite is unnoticed.  Bite marks from 
a bat can go unnoticed and often disappear in a short time frame.  Post-exposure prophylaxis for 
individuals that have not been previously immunized for rabies include four intramuscular doses 
on days 0 (day of first vaccine), 3, 7 and 14 (Centers for Disease Control and Prevention, 2011).  
Individuals that have previously been immunized and have documentation of virus neutralizing 
antibody production in response to the initial rabies immunizations will receive two booster 
doses at days 0 (day of first vaccine) and 3.  Table 1.2.  Rabies immune globulin (RIG) is also 
administered with post-exposure prophylaxis for individuals that have never previously received 
rabies prophylaxis.  Two types of RIG exist that are administered around the world, human 
rabies immune globulin (HRIG) and equine rabies immune globulin (ERIG).  RIG is an injection 
that is administered on around the wound as RIG should be infiltrated where the teeth and saliva 
penetrated into the skin (Centers for Disease Control and Prevention, 2014).  “Rabies immune 
globulin is a sterile solution of antibodies that provides individuals with immediate short-term 
protection against rabies” (Government of Saskatchewan, 2014, pg. 1).  RIG is administered on 
day 0, the same day the first dose of post-exposure prophylaxis is administered.  RIG is 
administered as the antibodies provide short passive immunity to protect against the rabies virus 
while the individual’s body is in process of producing antibodies from the prophylaxis (Mayo 
Clinic, 2014).  RIG is administered according to body weight, 20 IU/kg (Centers for Disease 
Control and Prevention, 2013).  Outlined below are the three categories that exist to determine if 
an individual is to receive RIG along with the 4 dose post-exposure prophylaxis.  Table 1.3. 
 Immunocompromised individuals receive a 5 dose regimen for post-exposure 
prophylaxis, administered on days O (day of first vaccine), 3, 7, 14 and 28 (Centers for Disease 
Control and Prevention, 2011).  Immunocompromised individuals also receive one dose of RIG 
on day 0.  For infants and children post-exposure prophylaxis and RIG is the same regimen as 
adults (Centers for Disease Control and Prevention, 2013). Pregnant women, unless 
immunocompromised, are directed to follow the 4 dose post-exposure and RIG regimen (Center 
for Disease Control and Prevention, 2010).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            




†World Health Organization (2013). WHO Expert Consultation on Rabies. WHO Technical Report Series 982. Second Report. Geneva.  
1 Exposure to rodents, rabbits or hares does not routinely require rabies post-exposure 
prophylaxis. 
2 If an n apparently healthy dog or cat in or from a low-risk area is placed under 
observation, treatment may be delayed. 
3 This observation period applies only to dogs and cats. Except for threatened or 
endangered species, other domestic and wild animals suspected of being rabid 
should be euthanized and their tissues examined for the presence of rabies 
antigen by appropriate laboratory techniques. 
4 Bites especially on the head, neck, face, hands and genitals are category III 
exposures because of the rich innervation of these areas. 
5 Post-exposure prophylaxis should be considered when contact between a human 
and a bat.  
 
Category of Exposure Type of exposure to a domestic or wild¹ 
animal suspected or confirmed to be 
rabid, or animal unavailable for testing 
Recommended Post-exposure Prophylaxis 
I Touching or feeding animals  
Licks on intact skin 
Contact of intact skin with secretions or 
excretions of a rabid animal or human case 
None, if reliable case history is available 
II Nibbling of uncovered skin  
Minor scratches or abrasions without 
bleeding 
Administer vaccine immediately².  Stop 
treatment if animal remains healthy 
throughout an observation period of 10 
days³ or is proven to be negative for rabies 
by a reliable laboratory using appropriate 
diagnostic techniques.  
III Single or multiple transdermal bites⁴ or 
scratches, licks on broken skin 
Contamination of mucous membrane with 
saliva (i.e. licks) 
Exposure to bats⁵ 
Administer rabies vaccine immediately and 
rabies immunoglobulin, preferable as soon 
as possible after initiation of post-
exposure prophylaxis.  Rabies 
immunoglobulin can be injected up to 7 
days after first vaccine dose 
administration.  Stop treatment if animal 
remains healthy throughout an 
observation period of 10 days or is proven 
to be negative for rabies by a reliable 
laboratory using appropriate diagnostic 
techniques. 
Categorization of exposure and indications for post-exposure rabies prophylaxis† 
Table 1.3 
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The first step of defense when bitten or scratched by any animal is proper wound care and 
management.  At the time of the bite or scratch, immediately wash the wound aggressively for 
several minutes with an abundant amount of soap and water.  This action can significantly 
decrease the risk for rabies as it physically decreases the amount of saliva and rabies virus from 
the wound (WHO, 2013).    Medical consultation immediately follows this crucial first-aid step 
of washing of the wound for determining the appropriate action.  “It is important to remember 
that rabies is a medical urgency but not an emergency.  Decisions should not be delayed” 
(Centers for Disease Control and Prevention, 2011, pg. 1).   
 
 Human Rabies Case 
       When discussing the rabies virus, pathogenesis, diagnosis and prophylaxis; it is often hard to 
put it into perceptive the events that take place and how an individual is affected from the rabies 
virus and why rabies is such an important public health concern.  To better understand, a human 
case from 2011 will illustrate the timeline from exposure to death disclosing the physical 
characteristics and final impact of the disease for one individual.    
 In January 2011 Private First Class (Pfc.) Kevin Shumaker, 24 years old, received a bite 
to his right hand from a feral/community dog while deployed in Afghanistan.  (Figure 1.11).  As 
Pfc. Shumaker was preparing for a new military assignment, on August 14
th
, 2011 he 
experienced shoulder pain and paresthesia (unexplained burning, tingling or pricking on the skin) 
during his travel to Fort Drum, New York from Grafenwöhr Germany (Morbidity and Mortality 
Weekly Report, 2012).  Prior to August 14
th
, 2011 Pfc. Shumaker was medically listed as a 
healthy individual.  Pfc. Shumaker began to have symptoms of nausea, vomiting and fever.   
August 15
th
, 2011 Pfc. Shumaker visited an emergency room where he was released (Morbidity 




, 2011 Pfc. Shumaker visited a 
chiropractor for the reasons of pain and then August 17
th
, 2011 Pfc. Shumaker made a second 
emergency room visit and again was released (Morbidity and Mortality Weekly Report, 2012).  
The diagnosis for both emergency room visits were listed as gastritis and neck tendonitis.  
August 18
th
, 2011 Pfc. Shumaker was having difficulties swallowing and on August 19
th
, 2011 
he was evaluated by the medical team at Fort Drum (Morbidity and Mortality Weekly Report, 
2012).  At this time Pfc. Shumaker’s symptoms were ataxia (lack of muscle control) and syncope 
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(partial or complete loss of consciousness) in which the medical team at Fort Drum sent him to 
the same emergency room that he previously visited on two occasions the few days prior 
(Morbidity and Mortality Weekly Report, 2012).  At the time of his arrival Pfc. Shumaker was 
dehydrated, lucid (easily understood) and hydrophobic and showing signs of aerophobia 
(Morbidity and Mortality Weekly Report, 2012).  Pfc. Shumaker advised he received a bite from 
a dog while in Afghanistan.  As a result of this knowledge and the aforementioned recent 
medical history, rabies was suspected.  The New York State Department of Health (NYSDOH) 
and the Centers for Disease Control and Prevention (CDC) were then immediately notified.  On 
that same day, August 19th, 2011, Pfc. Shumaker was transported to a second hospital 
(Morbidity and Mortality Weekly Report, 2012).  At the time he arrived he was becoming 
agitated and combative.   




 Upon his arrival, serum, saliva, CSF and a nuchal biopsy samples were taken and submitted for 




, 2011 the test results revealed rabies virus antigen in the 
hair follicles from the nuchal biopsy and viral RNA was revealed in the saliva and CSF 
Private First Class Kevin Shumaker.  Photo taken October 28, 2010 (Mail Online, 
2012). 
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(Morbidity and Mortality Weekly Report, 2012).  The CDC confirmed that rabies virus 
antibodies were detected in the serum and CSF.  On August 19
th
, 2011 the Milwaukee Protocol 
was implemented as a life saving measure for Pfc. Shumaker (Morbidity and Mortality Weekly 
Report, 2012).  Pfc. Shumaker was intubated, his pupils were dilated and his nervous system was 
not functioning properly.  Although no brain abnormalities were present a pacemaker was 
inserted due to complete heart blockage.  On August 20
th
, 2011 intracranial pressure was 
monitored by the placement of and external ventricular drain (Morbidity and Mortality Weekly 
Report, 2012).  August 21
st
, 2011 he suffered from a severe form of diabetes and on August 22
nd
 
there was severe brain swelling and acute respiratory distress (Morbidity and Mortality Weekly 
Report, 2012).  Small brain hemorrhaging began on August 28
th
 and on August 30
th
 severe brain 
hemorrhaging was documented (Morbidity and Mortality Weekly Report, 2012).  Family was 
advised that Pfc. Shumaker would unlikely recover and life support was ceased on August 31
st
, 
2011 (Morbidity and Mortality Weekly Report, 2012).   
 It is noteworthy to mention that a serum sample of Pfc. Shumaker from May 2011 was 
tested at the CDC in August 2011 and no specific rabies antibodies were found in this sample 
(Morbidity and Mortality Weekly Report, 2012).  This indicates that Pfc. Shumaker did not 
receive post-exposure prophylaxis or RIG following the dog bite to the right hand.    
 The timeline of the incidents that occurred from the time Pfc. Shumaker was in 
Afghanistan to the time of his unfortunate death from the rabies virus is represented below.  
Table 1.4.  
 Global Burden of Rabies 
 As stated by the World Organization for Animal Health (OIE), rabies is found on 6 of the 
7 world continents, Antarctica is the exception (OIE, 2014).  Globally, dogs are the main source 
of rabies as over 95% of human deaths result from infected dogs (Briggs, 2013).  According to 
current statistics provided by the Partners for Rabies Prevention an average of 61,000 human 
deaths occur annually from rabies (WHO, 2012).  Of those deaths, up to 60% are children under 
the age of 15 years old (Global Alliance for Rabies Control, 2013).  It is known that 84% of the 
61,000 human deaths occur in rural areas (WHO, 2012).   These rural areas are in “poor, remote 
regions where healthcare provision is minimal, and reporting even more so, plus awareness 
among the general population almost non-existent” (Briggs, 2013).   






 “And because most cases tend to be isolated, the statisticians tend to miss the big picture 
worldwide, which is that one person dies very eight minutes” (Briggs, 2013).  Underreporting, 
misdiagnosis, poor surveillance and the lack of infrastructure result in an underestimation of 
knowing the true burden of the disease on a global scale (WHO, 2012).  Over 95% of the human 
deaths from rabies occur in Asia and Africa (Global Alliance for Rabies Control, 2013) with 
India reporting the highest incidence globally (WHO, 2012).  The global distribution of risk for 
human rabies is depicted below (WHO, 2012).  Figure 1.12.  It is estimated that 3.3 million 
people live with the risk of rabies every day (Global Alliance for Rabies Control, 2014).   
            Whilst it is known that rabies impacts life on a physical, social and psychological level, 
rabies also impacts the world on an economic level.  In 2013 it was assessed that canine rabies 
results in $124 billion USD annually for global economic output (Global Alliance for Rabies 
Control 2013).  Whilst loss of human life is the most devastating impact of rabies, loss of human 
life also results in the highest financial cost (Global Alliance for Rabies Control, 2013).  The 
financial cost takes into account the deaths and the future lost earnings of the individuals that 
have died, which is known to directly impact the communities (Global Alliance for Rabies 
Control, 2013).  The next highest financial cost of rabies is the cost of rabies prophylaxis (Global 
Timeline of events that involved the human rabies case of Pfc. Kevin Shumaker 
(Morbidity and Mortality Weekly Report - MMWR, 2012) 
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Alliance for Rabies Control, 2013).  In reviewing specific costs around the world, we find that in 
the United States the CDC estimates that $300 million are spent on rabies prevention annually 
(WHO, 2012).  Although fox rabies has been eliminated from Western Europe, $6.5 billion USD 
is spent annually for a control program for fox rabies along the eastern boarder of the European 
Union (WHO, 2012).  In Asia, approximately $1.5 billion USD is spent annually on post-
exposure prophylaxis (WHO, 2012).  In taking a direct look at post-exposure prophylaxis, in 
Asia and individual pays 3.87% of their gross national income for a full series of post-exposure 
prophylaxis while and individual in Africa will pay 5.80% (WHO, 2012).  To put this into 
perspective, this constitutes the pay of working 51 days for the individual from Africa and 31 
days for the average individual in Asia (WHO, 2012). 
 
                                                                   Figure 1.12 
    
 
Global representation of the four risk categories for human rabies by countries or areas.  
The four risk categories are high, moderate, low, none (World Health Organization, 
2012).      
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In looking back to the year 1985, it is documented that Latin America and the Caribbean had an 
annual cost of $30 million USD from loss of livestock directly resulting from vampire bat rabies.  
  The economic cost of rabies is substantial.  “Rabies is the deadliest disease on earth with 
a 99.9% fatality rate” (Global Alliance for Rabies Control, 2014), and due to the result of 
growing populations of humans and canines around the world the economic cost of    
rabies along with the burden of human deaths will also continue to grow (WHO, 2012).    
  
Rabies-Free/Controlled Countries and Political Units 
 Rabies directly impacts the world both physically and economically.  Whilst the disease 
can detrimentally affect certain regions of the world, some areas of the world have successfully 
eradicated canine rabies, whereas other regions have obtained a status of rabies free, or rabies 
controlled.  In order for a country to be identified as rabies free, or rabies controlled, per the OIE 
the following provisions must be achieved:   
 The disease is notifiable (reported to appropriate authorities). 
 Effective disease surveillance has been implemented and is in operation. 
 Regulatory measures for control and prevention have been implemented.  This is to also 
include effective importation procedures. 
 Two years free from having an indigenous case of rabies in animals and man.  It is 
noteworthy to mention that isolating Australian or European Bat Lyssavirus would not 
affect this status. 
 No imported case of carnivores outside of the quarantine station has been confirmed with 
rabies for the previous six months.     
Regions of the world that have achieved and are currently maintaining a rabies-free status are 
listed below.  Table 1.5.  As aforementioned, the physical and economic cost of rabies is 
projected at $124 billion USD annually.  Do to the severity of the disease, physically and 
economically, once a region achieves rabies-free status, maintaining such status is vital.  The 
OIE specifically outlines the following recommendations in order to ship dogs and cats into 
rabies-free regions from countries that are considered infected with rabies: 
 Veterinary authorities must provide an international veterinary certificate that confirms 
the animal has not shown clinical signs of rabies within the past 48 hours of shipment. 
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 The animals must be permanently identified (such as tattoo or microchip) and that 
identifier must be listed on said certificate. 
 The animal must be vaccinated for rabies, and received not less than six months or more 
than one year prior to shipment.  The initial rabies vaccine should have been administered 
while the animal was at least 3 months old in age.  The vaccine is to be from an 
inactivated virus vaccine or from a recombinant vaccine that expresses the rabies virus 
glycoprotein.  
 The animal must be subjected to an antibody test not less than three months or more than 
twenty four months prior to shipment.  The antibody test must reflect that the animal is 
carrying an antibody response of at least 0.5 IU/mL, which meets WHO 
recommendations.   
 Animals that have not been vaccinated following the above noted criteria, the importing 
country can require the animal be placed in quarantine at a quarantine location within that 
countries territory for six months.  
 






















Africa Cape Verde, Mauritius, Reunion, Sao Tome, and Principe, Seychelles 
Americas North: Bermuda, Saint Pierre and Miquelon 
Caribbean: Antigua and Barbuda, Aruba 
The Bahamas, Barbados, Cayman Islands, Dominica, Guadeloupe, Jamaica, Martinique, 
Montserrat, Netherlands, Antilles, Saint Kitts (Saint Christopher) and Nevis, Saint Lucia, Saint 
Martin, Saint Vincent and Grenadines, Turks and Caicos, Virgin Islands (UK and US) 
Asia and the 
Middle East 
Hong Kong, Japan, Kuwait, Malaysia (Sabah), Qatar, Singapore, United Arab Emirates 
Europe1 Albania, Austria, Belgium, Corsica, Cyprus, Czech Republic, Denmark, Finland, France, 
Germany, Gibraltar, Hungary, Iceland, Ireland, Isle of Man, Liechtenstein, Luxembourg, 
Monaco, Netherlands, Norway (except Svalbard), Portugal, Slovakia, Slovenia, Spain (except 
Ceuta and Melilla), Sweden, Switzerland, United Kingdom 
Oceania2 Australia2 , Cook Islands, Fiji, French Polynesia, Guam Hawaii, Kiribati, Micronesia, New 
Caledonia, New Zealand, Northern Mariana Islands, Palau, Papua New Guinea, Samoa, 
Vanuatu 
1. Bat lyssaviruses have been reported throughout Europe, including areas that are reportedly free of rabies in other wild mammals. 
2. Most of Pacific Oceania is reportedly “rabies-free”, with the exception of Australia, where lyssaviruses in bats have been reported, as 
well as fatal human rabies cases.   
 
These recommendation and provisions are strictly enforced and followed throughout the world 
by governing bodies.  In the event an individual is choosing to ship a dog or cat to a rabies-free 
region these guidelines must be adhered to.  Failure to adhere to these guidelines can, and has, 
resulted in euthanasia of the animal.   
 
Regions of the world that are currently rabies-free (Centers for Disease Control and Prevention, 2013) 
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CHAPTER 2 – CAPSTONE EXPERIENCE 
  
Rabies Virus Testing Methodologies 
 Rabies is a public health concern for both, countries that are considered infected with 
rabies and rabies-free regions.  In rabies-free regions, new or previously identified rabies 
serotypes can be introduced or re-introduced at any time.  Until a day comes where rabies is 
eliminated on a global scale in canines and wildlife, “public health management of humans at 
risk of exposure to rabies will continue to depend heavily on rabies immunization, including both 
pre-exposure and post exposure prophylaxis, to prevent infection and death” (Rabies, 2
nd
 Edition, 
2007, pg. 548).  Continuous efforts of animal rabies vaccination programs are also critical in 
public health management for rabies prevention and control in which herd immunity is essential.   
 In order to successfully monitor such management programs, utilizing the appropriate 
testing methodologies to ascertain antibody response is vital.  As demonstrated throughout this 
paper, a variety of scenarios exists in which precisely measuring a rabies immunological 
response is critical in pre and post mortem subjects.  Recall, this is to include evaluating a 
humoral response to a vaccine, as well as, for diagnosing subjects suspected of having rabies.  
Throughout the decades, various testing methodologies have been developed.  These testing 
methodologies differ in how they detect rabies virus antibodies along with the ease and 
practicality at which they are performed (Rabies, 2
nd
 Edition, 2007).  “Methods available for the 
detection and measurement of rabies virus-specific antibodies are either antigen-binding assays 
or virus-neutralization assays” (Moore, Hanlon, 2010, Pg. 2).  The virus neutralizing assays 
consist of the Rapid Fluorescent Focus Inhibition Test (RFFIT) and the Fluorescent Antibody 
Virus Neutralization (FAVN) test.  Antigen-binding assays consist of Enzyme-Linked 
Immunosorbent Assay (ELISAs) and Indirect Immunofluorescence Assay (IFAs).  It is important 
to understand how these testing methodologies differ.  RFFIT and FAVN identify and measure 
rabies neutralizing antibodies (virus-neutralizing assay) in a sample.  Figure 2.1.  Whilst ELISAs 
and IFAs identify and measure antigen-binding antibodies (antigen-binding assay).  Figure 2.2.  
To further explain, “the outcome of a virus-neutralizing assay is based on a measurement of virus 
growth in cell culture, i.e., defining whether virus escapes neutralization or not” (Moore, Hanlon, 
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2010, Pg. 2). “Antigen-binding assays…are detected, quantified, and characterized by their 
ability to bind to various rabies virus antigens” (Moore, Hanlon, 2010, Pg. 2).  As these two 
testing methodologies; virus-neutralizing assays and antigen-binding assays; differ in their 
identifications and measurements, the results (measured in IU/mL) of each assay should not be 
equally comparable to one another.  For further understanding, IU/mL is defined as a substance 
(i.e., antibodies), that are detected (in this scenario, serum or CSF), which result in a biological 
response (i.e., adhering to the rabies virus) (Dictionary.com, 2014).   
 In reference to determining sufficient levels of immune response to the rabies virus, the 
WHO has set global standards that any subject with a result of less than 0.5 IU/mL is not 
adequately protected against rabies (WHO, 2012).  This global standard of 0.5 IU/mL is 
currently utilized for sample results for both virus-neutralizing assays and antigen-binding 
assays.  The 0.5 IU/mL standard was set by a working group in 1978 at the Joint WHO/IABS 
Symposium after reviewing several clinical trials (Moore, 2013).  The clinical trials that were 
reviewed to determine the 0.5 IU/mL standard were tested utilizing virus-neutralizing assays, and 
the clinical trials were a ‘point-in-time’ reading, as the samples tested were collected 1 month 
following vaccination (Moore, 2013).  As a result of utilizing the virus-neutralizing assay to set 
the 0.5 IU/mL standard; along with a point-in-time aspect, the idea of accepting a set global 
standard of 0.5 IU/mL for other testing methodologies (i.e., ELISAs and IFAs) is inaccurate.   
 ELISAs have been compared to virus-neutralization assays in which results were found to 
be similar, and noted as fair to good (Moore, 2013).  These findings are not astonishing as each 
testing methodology measures specific antibody responses.  It is important to note that due to the 
difference between the testing methodologies, results will not be consistent between subjects for 
reasons of Ig subclasses, various affinities, neutralizing abilities and unique polyclonal responses 
(Moore, 2013).  The Kansas State University Rabies Laboratory previously completed and in-
house investigation on comparing a commercial ELISA kit (Bio-Rad Platella Rabies Kit II) with 
the RFFIT (Moore, 2013).  The KSU Rabies Laboratory utilized clinical trial samples, over set 
periods of time, just as the working group identified the 0.5 IU/mL for global standards (Moore, 
2013).  The result of this in-house investigation echoes the concept that utilizing the 0.5 IU/mL 
standard for the two assays (virus-neutralization and antigen-binding) “…will never result in 
agreement for all individuals” (Moore, 2013, Poster).  It was further stated that “evaluating the 
kinetics of the RVNA/anti-glycoprotein response, combined with laboratory validation of the 
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specific test method and consideration of the use of the results (vaccine efficacy, determination 
of booster, detection of vaccine bait-uptake) is a logical approach for setting a useful cut-off for 
both RFFIT and ELISA methods” (Moore, 2013, Poster).  Once more, evidence supports that the 
two assay testing  methodologies(virus-neutralizing and antigen-binding), although similar, 
consist of substantial differences to warrant further investigation on determining appropriate 
standards for each assay as one global standard is not adequate. 
 
             Investigating the Performance of a Rabies ELISA 
 In looking further into the analysis of appropriate cut-off values for both virus-
neutralization assays and antigen-binding assays, I had the unique opportunity to partner up with 
Zoetis to investigate their commercial Indirect ELISA.  Zoetis, a global leading animal health 
company, brought forward their commercial Indirect ELISA kit (SERELISA
®
 Rabies Ab Mono 
Indirect) to investigate the performance of a rabies ELISA testing methodology to determine 
adequate immune response levels to rabies vaccines.  This investigation also allows for further 
exploration of the differing characteristics of the testing methodologies and to explore potential 
differing cut-off values, as aforementioned.  
  The Zoetis Indirect ELISA is a commercially available ELISA kit designed to detect 
anti-rabies antibodies in canine and feline serum samples (Zoetis, 2014).  (Figure 2.3).  The 
indirect ELISA is quantitative, in which results are interpreted in comparison to a standard curve 
to precisely calculate the antibody concentration in each sample well.  Quantitative analysis is 
interpreted versus qualitative, qualitative simply indicates by color change if the antibody is 
present (at a pre-determined statistical level) in the sample well.  This kit also adheres to the 
WHO global standard in which a minimum of 0.5 IU/mL result is required to determine adequate 
protection per sample, as aforementioned.  You shall recall that the WHO standards were 
determined by results from virus-neutralizing assays, and this ELISA is an antigen-binding 
assay.  To date, the WHO does not have adequate recommendations for immune response levels 
for ELISAs (antigen-binding assays).  The kit insert outlines the contents included, steps and 
dilutions required to perform the ELISA along with how to interpret results (Appendix A) 
(Zoetis, 2014).                                             
 












Rabies neutralization assays involve mixing of fixed amount of live rabies virus with serum 
containing RVNA antibodies (Y shapes) and allowing neutralization to occur through interaction 
of rabies virus neutralizing antibodies with the rabies virus glycoprotein (spikes). Non-
neutralized rabies virus infects cells added to the mixture.  Rabies virus in the infected cells in 
detected with fluorescence (Y shape with star attached) (Moore, 2007). 









   
The long term objective for the investigation of the SERELISA
®
 Rabies Ab Mono 
Indirect ELISA is dual in nature.  The first objective will investigate the performances of this 
ELISA on human sample origin for the appreciation of the protection status obtained after Rabies 
vaccination.  The second objective is to establish standardization curves and appreciate the 
Illustration of the binding assay in an indirect ELISA using rabies virus glycoprotein (short 
straight vertical lines) bound to microtiter wells (bottom horizontal line).  Presence of rabies 
virus glycoprotein binding antibodies (Y-shaped symbols) is detected by an enzyme-labeled 
antiglobulin or Staphlococcus aureus protein A (Y shapes with star attached).  A detection 
system involving the addition of an enzyme substrate leads to a color change (Moore, 2007).   
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robustness of the test when using different reference sera (WHO-1, WHO-2, OIE and Kansas 
State University).  The capstone portion of this paper will focus on the initial phases of testing 
the different reference sera (WHO-1, WHO-2, OIE and KSU).  The investigating of the 
performances of this ELISA on human samples will directly follow; however, will not fall within 
the timeline of this paper.  Investigation of the SERELISA
®
 Rabies Ab Mono Indirect ELISA 
was performed at the Kansas State Veterinary Diagnostic Rabies Laboratory in Manhattan, KS.     
To being the process of working with Zoetis, an IRB (Research Involving Human Subjects) 
application was required for approval through Kansas State University (KSU).  The IRB 
application (Appendix B) was submitted, reviewed, investigated and approved (IRB #7012) by 
the KSU Committee for Research Involving Human Subjects on January 27, 2014.  In 
conjunction with the IRB application process a USDA (United States Department of Agriculture) 
Veterinary Biological Product Permit was pursued.  The USDA Veterinary Biological Product 
Permit (Appendix C) for Research and Evaluation was approved on November 22, 2013.   The 
approved IRB and USDA permits were forwarded to Zoetis.  Immediately following, I then 
began to draft a protocol for this project, as required by KSU and Zoetis.  Title of the protocol is 
“Validating And Standardization Of The Synbiotics Rabies ELISA Test, SERELISA
®
 Rabies Ab 
MONO Indirect, For Detection Of Anti-Rabies Antibodies In Individual Human Serum”.  The 
drafted protocol (Appendix D) was submitted to the KSU Rabies Laboratory Director and Zoetis 
Director of Global Marketing for review.  Upon acceptance of the drafted protocol Zoetis then 
moved forward internally to secure a set number of the ELISA kits to be shipped directly to the 
KSU Rabies Laboratory.   The laboratory received the ELISA kits Monday morning, March 31
st
.  
A conference call between me and the KSU Rabies Laboratory Director and Zoetis Director took 
place that Monday afternoon.  After some ‘tweaking’ of the outlined microplates in the protocol, 
testing of the reference sera on the ELISA plates began that same afternoon.  Testing of the 
reference sera on the Indirect ELISA continued beyond the time of writing this paper.  The 
preparations and results that can be shared up to the end point of this paper are discussed.   
  
 








            The initial physical preparation for the first test, and all consecutive tests to follow; 
consisted of attaining stock samples of the reference sera (WHO-1, WHO-2, OIE, and KSU).  
The stock reference sera were provided, as were all additional supplies not provided within the 
contents of the Indirect ELISA kit, by the KSU Rabies Laboratory.  For documentation purposes, 
the titration and label of each reference sera (WHO-1, WHO-2, OIE, and KSU) are identified.  
Table 2.1. Each stock reference sera (WHO-1, WHO-2, OIE, and KSU) was reconstituted and 
diluted to the serial dilutions listed below.  Table 2.2.  The reference sera and their serial 
dilutions, as illustrated in Table 2.2, will be utilized to validate the Indirect ELISA and determine 
which reference sera’s will be utilized alongside the human serum samples when tested.   
The microplate set up for the first ELISA run (identified as plate 10 – 1
st
 half) was set up as 





Photograph of the Zoetis SERELISA
®
 Rabies Ab Mono Indirect Kit and its contents per kit 
(Zoetis, 2014). 




Reference Sera IU/mL Label 
OIE 6.7 Batch 3 
WHO-1 59.0 Lot R3 US Standard 
WHO-2 30.0 RAI 









 OIE WHO-1 WHO-2 KSU 
IU/mL 6.7 59.0 30.0 59.0 → 17.0 
Dilution 1 6.7 5.9 6.0 6.0 
Dilution 2 2.23 1.97 2.0 2.0 
Dilution 3 0.67 0.59 0.6 0.6 
Dilution 4 0.447 0.39 0.4 0.4 
Dilution 5 0.223 0.197 0.2 0.2 
Dilution 6 0.067 0.059 0.06 0.06 





Titration and label identifier for each reference sera utilized for the SERELISA® 
Rabies Ab MONO Indirect ELISA (Moore, 2014).  
Reconstitution and serial dilutions of each reference sera utilized for the 
SERELISA® Rabies Ab MONO Indirect ELISA (Moore, 2014). 
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Table 2.3 
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Upon completion of the test procedures, each plate is placed into an automated plate reader, in 
which is the optical density (OD) is measured bichromatically (450 and 630 nm) (Zoetis, 2014).  
The data from the automated plate reader was submitted directly to Zoetis to incorporate into 
their program for interpretation and review.  Upon interpretation and review, it was noted that 
the end results of the plate was not as expected.  It was discussed per telephone that the WHO-1 
Plate 10, 1
st
 Half, Set up and expected results. 
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and WHO-2 serial dilutions were too similar in their results; no other detailed points were noted.  
This outcome resulted in making changes to the design of plate 1 listed in the protocol.    Plate 1 
was now to be set up as with updated serial dilution for the WHO-1 reference sera.  Table 2.4.  It 
was determined that Plate 2 would remain as projected in the protocol.  Table 2.5.  The new 
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Plate 1 – Set Up & Expected Results 






Upon completion of the test performance of Plate 1 and 2, the data identified (OD readings) from 
the automated plate reader was again forwarded to Zoetis for interpretation and review.  
Consultation revealed that while the plates consisted of good, consistent and clean results 
throughout, an excess of variation was detected between a few of the duplicated serial dilutions 
than projected.  This resulted in one validation between the reference sera.  In order for any of 
the reference sera to be validated on the microplate, a >.0.95 of the correlation coefficient 
between the Neperian logarithm (ln) ODs and in ln Rabies Ab concentrations for the reference 
sera is needed.  The values attained were identified at 86.2, 97.2, 94.8, 83.8, 91.7 and 88.3 for 
Plate 1 and 92.6, 94.3, 87.9, 81.1, 85.1 and -19.5 for Plate 2.  Several values were in reach of the 
>.0.95 needed for validation, with one reference sera reaching the validation point.  These results 
led to further discussion, in which it was decided that these two microplates would be re-run 
whilst removing some of the reference sera and changing the WHO-1 and WHO-2 dilutions, 
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Plate 2 – Set Up & Expected Results 
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cutting the dilutions in half. The second run for Plate 1 and Plate 2 were now identified with the 
following reference sera and dilutions for the WHO-1 and WHO-2.  Table 2.6.    
 






Upon the completion of test performance for Plate 1 and Plate 2, second run, the OD values from 
the automated plate reader was submitted to Zoetis for interpretation and review.  The overall 
results of this run reflected that the WHO-1 and WHO-2 reference sera gave improved end 
results. Recall, that in order for any of the reference sera to be validated on the microplate, a > 
0.95 of the correlation coefficient between the Neperian logarithm (ln) ODs and in ln Rabies Ab 
concentrations for the reference sera is needed.  The ending values attained in this run were 
identified at 93.2, 94.6, 93.1, 86.9, and 93.5 for Plate 1 and 96.9, 94.8, 89.0, 84.4, 90.9 and -13.6 
for Plate 2.  Concern did not weigh heavily on the -13.6 result as this reference sera has been 
 
1 2 3 4 5 6 7 8 9 10 11 12 






















































































































































































             
 
1 2 3 4 5 6 7 8 9 10 11 12 



























































































































































































            
New Scheme for plate number 1 and plate number 2 
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performing in the 80 and 90
th
 percentile in all consecutive runs. Also note, one of the reference 
sera was above the 0.95 in Plate 1, resulting in a second validation result.  In discussing this run 
per telephone, Zoetis, KSU and I discussed some possible methods to slightly alter the next run 
to obtain ideal results.  Items such as performing plates in parallel with multiple technicians, 
additional plate washings, and running the duplicate reference sera in triplicate were discussed.  
As discussions pursued, it was identified that the plate washing steps were performed manually, 
verses by automated machine.  This reflection led to further discussion of the differences in the 
end results that might be attained by utilizing the automated plate washer.  It is believed that the 
automated plate washer would remove additional excess ‘loose’ antibodies, which would result 
in a more accurate reading of the OD values.  The decision was then unanimously made to run a 
microplate with the duplicate reference sera (WHO-1 and WHO-2) in a series of three with both 
manual and electronic wash cycles.  The first duplicate set of WHO-1 and WHO-2 would be 
washed manually, the second duplicate set of WHO-1 and WHO-2 would be washed by the 
automated plate washer, and the third duplicate set of WHO-1 and WHO-2 would be washed 
manually.  It is noteworthy to mention that the Indirect ELISA calls for two wash cycles.  Thus 
the second duplicate set of WHO-1 and WHO-2 was to receive two washes from the automated 
plate washer.  As a result of the pate washer not functioning properly, this duplicate set was 
washed manually for the first wash and then by the automated plate washer for the second wash 
as the error was resolved.  The plate scheme for this run was to be performed as follows.  Table 






The end results of this run and analysis and interpretation by Zoetis were still pending at the time 
this paper was due to the committee.  As I continue to move forward in this project with Zoetis 
and Kansas State University, we are all optimistic that the final goals and objectives will result in 
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New plate scheme for the next scheduled run. 
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CHAPTER 3 – CONCLUSIONS & RECOMMENDATIONS 
 
 Conclusion 
 Rabies is a neurological disease that has affected the lives of animals and man for 
centuries.  Rabies is known as the deadliest disease to man with a 99.9% fatality rate (GARC, 
2014) and is found on every continent excluding Antarctica (WHO, 2014).  This disease cost 
lives and impacts culture, religion and economics, devastating communities globally. Annually, 
rabies claims the lives of 61,000 (WHO, 2012) humans, which is grossly under reported as 84% 
(WHO, 2012) of the deaths occur in rural areas in the poorest countries.  Majority of these 
human deaths, up to 60%, are children ages 15 and younger (GARC, 2013).  Asia and Africa 
result in majority of the human annual deaths, 95% (WHO, 2012) with India having the highest 
fatality rate (GARC, 2013).  Human and animal prophylaxis, in conjunction with proper wound 
management, have proven to prevent and control the virus, however, limiting factors prevent 
successful distribution and administration.  These factors include lack of government 
infrastructure, culture and religious beliefs, lack of funding for the vaccines, location of vaccine 
administration and more.  Whilst rabies can occur in all mammals, 95% of human deaths result 
from infected canines (Briggs, 2013).  Rabies is 100% preventable in humans and can be 
eradicated in canines through successful vaccination programs.  Individuals and organizations 
around the world spend tireless efforts on building and establishing educational rabies programs 
and vaccine incentives.  Although there has been great success in these efforts, it is still not 
enough as people continue to die from rabies.  Rabies cost the world an astonishing $124 billion 
USD annually (GARC, 2013) and as long as populations continue to grow for humans and 
canines, the cost and economic burden will also continue to grow (WHO, 2012).  As a result of 
this horrific disease, the importance of prophylaxis and passive immunity are critical in the event 
of medically managing an exposure, and preventing exposures.  Utilizing the appropriate testing 
methodologies with rigorously defined recommendations to ensure adequate protection against 
the rabies virus is vital.   
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 Recommendations 
 As human and canine populations continue to grow, the cost and economic burden will 
also continue to grow (WHO, 2012).  In order to reduce the burden of rabies there is a need for 
further solid foundation for prevention and control.  Canine rabies can be eradicated with proper 
animal vaccination distribution and administration in conjunction with an ORV program.  As 
obstacles exist for free roaming canines, additional efforts with ORV must be implemented.  
ORV would provide crucial benefits for saving lives and decreasing the economic burden in the 
poorest areas.  Contraception initiatives with vaccine programs and ORV also promise to 
enhance the control of rabies globally (Rupprecht, 2011).  Minimizing human exposures to 
infected animals is also essential.  Ensuring prompt wound management and proper 
administration of prophylaxis (and RIG) for exposed individuals is critical.  Further use of 
effective blueprints and international advocacy for prevention and control is needed on a global 
scale.  In reference to research, additional studies are necessary for development of 
recommendations that are science based.  Well-designed studies are needed for additional data in 
the following areas; potential shedding of virus in milk, PEP protocols for domestic animals, 
earliest age at which rabies vaccine is most effective, viral shedding periods for domestic 
livestock and lagomorphs and the ecology of rabies in wildlife species (Compendium of Animal 
Rabies Prevention and Control, 2011).  Further investigation into the differing testing 
methodologies is also warranted to identify suitable global standards and recommendations for 
each assay, to ensure immune response levels are adequate for  protection against the rabies 
virus.  Rabies is 100% preventable in humans and the eradication of canine rabies is obtainable 
through vaccine and contraceptive campaigns.  Implementing national programs with effective 
surveillance and control efforts are imperative as is obtaining political commitments globally and 
implementing additional global standards and recommendations for measuring immune 
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APPENDIX B – KSU IRB APPROVED APPLICATION 
 
FOR OFFICE USE ONLY:  IRB Protocol # _____________________   Application Received:   
_____________   
Routed: _________   Training Complete: ____________________ 
 
Committee for Research Involving Human Subjects (IRB) 
Application for Approval Form 
Last revised on January 2011 
 
ADMINISTRATIVE INFORMATION:  
 
  Title of Project: (if applicable, use the exact title listed in the grant/contract application) 
 Cut-off Values for Rabies Serology Methods - Are They Interchangeable? 
 
  Type of Application:   
   New/Renewal   Revision (to a pending new application)  
  Modification (to an existing #______ approved application) 
 
  Principal Investigator: (must be a KSU faculty member) 
 Name: Dr. M. M. Chengappa Degree/Title: Department Head, 
University Distinguished 
Professor 
 Department: Diagnostic Medicine and 
Pathobiology 
Campus Phone: 785-532-4403 
 Campus Address: Mosier Hall K-222 Manhattan, KS 
66506 
Fax #: 785-532-4039 
 E-mail chengapa@vet.k-state.edu  
 
  Contact Name/Email/Phone for 
Questions/Problems with Form: 
Mylissia Smith Stukey / mstukcy@vet.k-state.edu / 785-532-4621 or 
Susan Moore / smoore@vet.k-state.edu / 785-532- 4472  
 
  Does this project involve any collaborators not part of the faculty/staff at KSU? (projects with non-KSU 
collaborators may require additional coordination and approvals): 
  No 
  Yes 
 
  Project Classification (Is this project part of one of the following?): 
  Thesis 
  Dissertation 
  Faculty Research 
     Other: MPH Capstone  
 Note: Class Projects should use the short form application for class projects. 
 
  Please attach a copy of the Consent Form: 
  Copy attached 
  Consent form not used 
 
  Funding Source:  Internal      External (identify source and 
attach a copy of the sponsor’s grant application or contract as 
submitted to the funding agency) 
            Copy attached                  Not applicable 
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  Based upon criteria found in 45 CFR 46 – and the overview of projects that may qualify for exemption 
explained at http://www.hhs.gov/ohrp/policy/checklists/decisioncharts.html , I believe that my project using 
human subjects should be determined by the IRB to be exempt from IRB review: 
  No 
  Yes (If yes, please complete application including Section XII. C. ‘Exempt Projects’; remember 
that only the IRB has the authority to determine that a project is exempt from IRB review) 
   
If you have questions, please call the University Research Compliance Office (URCO) at 532-3224, or comply@ksu.edu 
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Human Subjects Research Protocol Application Form 
 
The KSU IRB is required by law to ensure that all research involving human subjects is adequately reviewed for 
specific information and is approved prior to inception of any proposed activity.  Consequently, it is important that 
you answer all questions accurately.   If you need help or have questions about how to complete this application, 
please call the Research Compliance Office at 532-3224, or e-mail us at comply@ksu.edu. 
 
Please provide the requested information in the shaded text boxes.  The shaded text boxes are designed to 
accommodate responses within the body of the application.  As you type your answers, the text boxes will expand as 
needed.  After completion, print the form and send the original and one photocopy to the Institutional Review Board, 
Room 203, Fairchild Hall. 
 
Principal Investigator: Dr. M. M. Chengapp 
Project Title: Cut-off Values for Rabies Serology Methods - Are They Interchangeable? 




Is this a modification of an approved protocol?    Yes    No  If yes, please comply with the following: 
If you are requesting a modification or a change to an IRB approved protocol, please provide a concise description of all of the changes that you 
are proposing in the following block.   Additionally, please highlight or bold the proposed changes in the body of the protocol where appropriate, 
so that it is clearly discernable to the IRB reviewers what and where the proposed changes are.   This will greatly help the committee and 
facilitate the review.  




 NON-TECHNICAL SYNOPSIS (brief narrative description of proposal easily understood by nonscientists): 
Vaccine equivalency is determined partly by seroconversion levels.  Seroconversion is a process of 
developing antibodies in the serum to combat infection.  Medical decisions and advice are based on such 
seroconversion levels for vaccines, for example, vaccine booster administration.  In reference to rabies 
vaccines, this seroconversion level is recognized to be 0.5 IU/mL by the World Health Organization 
(WHO).  The IU/mL is the potency level of antibodies per mL recognized as an effective response to the 
rabies vaccine.  This project investigates weather or not the 0.5 IU/mL level (recognized by the WHO) can 
be used interchangeably between testing methodologies for vaccine response interpretations.  To 
determine sufficient rabies antibody levels from serum, the testing methodologies measure different 
ascepts of the antibody response leading to different testing interpretations.  For example, one testing 
methodology measures the antibody neutralizing function from the vaccine whilst another testing 
methodology measures the binding function of the rabies antibodies to a rabies viral protein.  As a result 
of these differences between testing methodologies, the result of the IU/mL (0.5) are not expected to be 
appropriate for all tests.  As a result, individual testing methodologies need to determine an independent  
value that represents an effective response to rabies vaccination.  This study will investigate and possibly 
determine the appropriate levels for each testing methodology.  This will allow for further education and 
information to medical professionals for improved decision making of when a vaccine booster is indeed 




BACKGROUND (concise narrative review of the literature and basis for the study): 
The 0.5 IU/mL level is recognized globally as indication of adequate response to vaccination in humans. 
Often forgotten are the circumstances of the origin of this determination. Reports from the WHO Expert 
Committee on Rabies (the 3rd/1957 through the 6th/1973) state that vaccination response be verified in 
the serum 1 month after vaccination by detection of RVNA, but no specific level is named. A Working 
Group convened during the 1978 Joint WHO/IABS symposium defined a cut-off after review of several 
clinical trial studies; concluding “that the serum be tested four weeks after the last inoculation and at that 
time a minimum value of 0.5 IU per ml be attained to demonstrate seroconversion.” In the WHO Expert 
Committee on Rabies Report in 1984 the 0.5 IU/mL cut-off noted as the level required 1 month after 
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vaccination and that booster vaccinations are required until that level is reached. The important points 
are: the level was determined based on results from serum neutralization methods (MNT and RFFIT); it 
was for specific time point (1 month after vaccination); and it was for a specified purpose (demonstrate 
seroconversion). To extrapolate this value to other methods, time points, and purposes is incorrect.  
Serum neutralization and ELISA rabies serology methods have been compared many times with similar 
findings: correlation is fair to good. This is not surprising as both are measuring, in different ways, the 
specific rabies antibody response to rabies vaccination. The reasons the comparison cannot be “good” for 
all samples are: the methods measure different characteristics of rabies antibodies (neutralizing function 
for SNs and binding function for ELISA); the normal response to rabies vaccination is polyclonal with 
various affinities, Ig subclasses, and neutralizing abilities, a unique polyclonal response per individual.  
This means the relationship of binding antibody measurement to neutralizing function will not be 
constant between individuals.  
 
II.     PROJECT/STUDY DESCRIPTION (please provide a concise narrative description of the proposed activity in 
terms that will allow the IRB or other interested parties to clearly understand what it is that you propose to do 
that involves human subjects.  This description must be in enough detail so that IRB members can make an 
informed decision about proposal). 
This project is a comparative study to compare the safety and immunogenicity between two human rabies 
vaccines.  It is an open study involving the serum of 189 healthy volunteers.  The serum will be divided 
into three groups (A, B and C).  Each group will consist of 63 serum samples that will have received one of 
the vaccines with a specific vaccine regimen.  Group A and B serum will been vaccinated with the same 
human vaccine with differing vaccine regimen days.  Group C serum will have been vaccinated with the 
second vaccine for the same vaccine regimen days as group B.  
 
 The samples received will consist of 5 blood draws from each individual.  The first blood draw will be on 
day 0 to determine a baseline.  The following blood draws will be utilized to monitor antibody production.  
All samples will be blinded and blood samples will have the rabies antibody concentrations evaluated by 
utilizing the Rapid Fluorescent Focus Inhibition Test (RFFIT) and an Enzyme Linked Immunoassay 
(ELISA).  
 
III. OBJECTIVE (briefly state the objective of the research – what you hope to learn from the study): 
To determine whether 0.5 EU/mL or another logical cut-off  level could be determined by evaluation of 
the response as measured by ELISA using clinical trials samples (over set time points), just as the 0.5 
IU/mL was established for SN methods. 
The objectives of this study are: 
1) To characterize the rabies antibody response to vaccination using an ELISA method that detects anti-
rabies glycoprotein IgG and to modify the method to detect anti-rabies glycoprotein IgM for additional 
characterization of the response. 
2) To evaluate the adequate response by comparing antibody levels (EU/mL vs. IU/mL). 
3) To determine if a correlation between ELISA results and RFFIT results can be made in the 
determination of adequate response for individuals and for a group. 
 
IV. DESIGN AND PROCEDURES (succinctly outline formal plan for study): 
A. Location of study: Kansas State University KSVDL Rabies Laboratory Manhattan, KS 
B. Variables to be studied: Human Blood Serum 
C. Data collection methods: (surveys, instruments, etc – 
PLEASE ATTACH) 
Receive serum samples by courier, RFFIT and 
ELISA testing methodologies, Reed and 
Muench calculation chart, International Unit 
calculation formula, Bio-Rad EU/mL 
calculation, Zoetis EU/mL calculation.   
D. List any factors that might lead to a subject 
dropping out or withdrawing from a study.  
These might include, but are not limited to 
emotional or physical stress, pain, 
inconvenience, etc.: 
NA 
E. List all biological samples taken: (if any) Human Blood 
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. RESEARCH SUBJECTS: 
A. Source: PHARMA-SURREY INTERNATIONAL, INC. #46 Bulusan St. Sta. Mesa 
Heights, Quezon City, Philippines.      
B. Number: 189 Serum Samples  
C. Characteristics: (list any unique 
qualifiers desirable for research 
subject participation) 
NA 
D. Recruitment procedures: (Explain how do you 
plan to recruit your subjects?  Attach any fliers, 
posters, etc. used in recruitment.  If you plan to 
use any inducements, ie. cash, gifts, prizes, etc., 
please list them here.) 
NA 
 
VI. RISK – PROTECTION – BENEFITS: The answers for the three questions below are central to human 
subjects research.  You must demonstrate a reasonable balance between anticipated risks to research participants, 
protection strategies, and anticipated benefits to participants or others. 
 
A. Risks for Subjects: (Identify any reasonably foreseeable physical, psychological, or social risks for 
participants.  State that there are “no known risks” if appropriate.) 
 NA 
B. Minimizing Risk: (Describe specific measures used to minimize or protect subjects from anticipated risks.) 
 NA 
C. Benefits: (Describe any reasonably expected benefits for research participants, a class of participants, or to 
society as a whole.) 
 NA 
 
In your opinion, does the research involve more than minimal risk to subjects?  (“Minimal risk” means that 
“the risks of harm anticipated in the proposed research are not greater, considering probability and magnitude, 
than those ordinarily encountered in daily life or during the performance of routine physical or psychological 
examinations or tests.”) 
 
 Yes  No 
 
VII. CONFIDENTIALITY:  Confidentiality is the formal treatment of information that an 
individual has disclosed to you in a relationship of trust and with the expectation that it will not be 
divulged to others without permission in ways that are inconsistent with the understanding of the 
original disclosure.  Consequently, it is your responsibility to protect information that you gather from 
human research subjects in a way that is consistent with your agreement with the volunteer and with 
their expectations.     If possible, it is best if research subjects’ identity and linkage to information or 
data remains unknown.    
Explain how you are going to protect confidentiality of research subjects and/or data or records.  
Include plans for maintaining records after completion.   
Samples are labeled with a ID number blinded to the laboratory. The laboratory does not receive or 
have access to personal information about the subjects providing the serum samples. 
 
VIII. INFORMED CONSENT: Informed consent is a critical component of human subjects research – it 
is your responsibility to make sure that any potential subject knows exactly what the project that you are 
planning is about, and what his/her potential role is.  (There may be projects where some forms of 
“deception” of the subject is necessary for the execution of the study, but it must be carefully justified to and 
approved by the IRB).  A schematic for determining when a waiver or alteration of informed consent may be 
considered by the IRB is found at http://www.hhs.gov/ohrp/policy/consentckls.html  Even if your proposed 
activity does qualify for a waiver of informed consent, you must still provide potential participants with basic 
information that informs them of their rights as subjects, i.e. explanation that the project is research and the 
purpose of the research, length of study, study procedures, debriefing issues to include anticipated benefits, 
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study and administrative contact information, confidentiality strategy, and the fact that participation is 
entirely voluntary and can be terminated at any time without penalty, etc.   Even if your potential subjects are 
completely anonymous, you are obliged to provide them (and the IRB) with basic information about your 
project.  See informed consent example on the URCO website.  It is a federal requirement to maintain 
informed consent forms for 3 years after the study completion. 
Yes No Answer the following questions about the informed consent procedures. 
  A. Are you using a written informed consent form? If “yes,” include a copy with this 
application.  If “no” see b. 
  B. In accordance with guidance in 45 CFR 46, I am requesting a waiver or alteration of 
informed consent elements (See Section VII above).  If “yes,” provide a basis and/or 
justification for your request. 
 NA 
  C. Are you using the online Consent Form Template provided by the URCO?  If “no,” does 
your Informed Consent  document has all the minimum required elements of informed 
consent found in the Consent Form Template? (Please explain) 
 As per discussion with Heath Ritter per telephone 1-14-14, 1:50 PM CST: The clinical trial 
is being performed and managed by Pharma-Surrey International, Inc. in the Philippines.  
Pharma-Surrey is submitting the blood samples to KSU for analysis for research purposes 
only.  As a result, the consent form template submitted here is the form Pharma-Surrey has 
on file signed by all healthy volunteers for this clinical trial.  In this specific situation the 
KSU IRB template is not needed for use.   
  D. Are your research subjects anonymous?  If they are anonymous, you will not have access 
to any information that will allow you to determine the identity of the research subjects in 
your study, or to link research data to a specific individual in any way.  Anonymity is a 
powerful protection for potential research subjects.  (An anonymous subject is one whose 
identity is unknown even to the researcher, or the data or information collected cannot be 
linked in any way to a specific person). 
 NA 
  E. Are subjects debriefed about the purposes, consequences, and benefits of the research? 
Debriefing refers to a mechanism for informing the research subjects of the results or 
conclusions, after the data is collected and analyzed, and the study is over.   (If “no” 
explain why.)  Attach copy of debriefing statement to be utilized. 
 NA 
 
*It is a requirement that you maintain all signed copies of informed consent documents for at least 3 
years following the completion of your study.  These documents must be available for examination and 
review by federal compliance officials. 
 
IX.    PROJECT INFORMATION:  (If you answer yes to any of the questions below, you should explain them  
 in one of the paragraphs above) 
 
Yes No Does the project involve any of the following? 
  a. Deception of subjects 
  b. Shock or other forms of punishment 
  c. Sexually explicit materials or questions about sexual orientation, sexual experience or 
sexual abuse 
  d. Handling of money or other valuable commodities 
  e. Extraction or use of blood, other bodily fluids, or tissues 
  f. Questions about any kind of illegal or illicit activity 
  g. Purposeful creation of anxiety 
  h. Any procedure that might be viewed as invasion of privacy 
  i. Physical exercise or stress 
  j. Administration of substances (food, drugs, etc.) to subjects 
  k. Any procedure that might place subjects at risk 
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  l. Any form of potential abuse; i.e., psychological, physical, sexual 
  m. Is there potential for the data from this project to be published in a journal, presented at a 
conference, etc? 
  n. Use of surveys or questionnaires for data collection 
IF YES, PLEASE ATTACH!! 
 
 
X.   SUBJECT INFORMATION:  (If you answer yes to any of the questions below, you should explain them in 
one of the        paragraphs above) 
 
Yes No Does the research involve subjects from any of the following categories? 
  a. Under 18 years of age (these subjects require parental or guardian consent) 
  b. Over 65 years of age 
  c. Physically or mentally disabled 
  d. Economically or educationally disadvantaged 
  e. Unable to provide their own legal informed consent 
  f. Pregnant females as target population 
  g. Victims 
  h. Subjects in institutions (e.g., prisons, nursing homes, halfway houses) 
  i. Are research subjects in this activity students recruited from university classes or volunteer 
pools?  If so, do you have a reasonable alternative(s) to participation as a research subject 
in your project, i.e., another activity such as writing or reading that would serve to protect 
students from unfair pressure or coercion to participate in this project?   If you answered 
this question “Yes,” explain any alternatives options for class credit for potential human 
subject volunteers in your study.  (It is also important to remember that:  Students must be 
free to choose not to participate in research that they have signed up for at any time 
without penalty.  Communication of their decision can be conveyed in any manner, to 
include simply not showing up for the research.) 
   NA 
  j. Are research subjects audio taped?  If yes, how do you plan to protect the recorded 
information and mitigate any additional risks? 
   NA 
  k. Are research subjects’ images being recorded (video taped, photographed)?  If yes, how do 
you plan to protect the recorded information and mitigate any additional risks? 
   NA 
 
 
XI. CONFLICT OF INTEREST:  Concerns have been growing that financial interests in research may 
threaten the safety and rights of human research subjects.   Financial interests are not in themselves 
prohibited and may well be appropriate and legitimate.  Not all financial interests cause Conflict of 
Interest (COI) or harm to human subjects.  However, to the extent that financial interests may affect the 
welfare of human subjects in research, IRB’s, institutions, and investigators must consider what actions 
regarding financial interests may be necessary to protect human subjects.   Please answer the following 
questions: 
 
Yes No  
  a. Do you or the institution have any proprietary interest in a potential product of this research, 
including patents, trademarks, copyrights, or licensing agreements?   
  b. Do you have an equity interest in the research sponsor (publicly held or a non-publicly held 
company)? 
  c. Do you receive significant payments of other sorts, eg., grants, equipment, retainers for consultation 
and/or honoraria from the sponsor of this research?     
  d. Do you receive payment per participant or incentive payments?  
  e. If you answered yes on any of the above questions, please provide adequate explanatory information 
so the IRB can assess any potential COI indicated above.  
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XII.  PROJECT COLLABORATORS: 
 
A. KSU Collaborators – list anyone affiliated with KSU who is collecting or analyzing data: (list all 
collaborators on the project, including co-principal investigators, undergraduate and graduate students) 
 
Name:  Department:  Campus Phone:  Campus Email: 
Susan Moore  KSVDL  785-532-4472  smoore@vet.k-state.edu 
Mylissia Smith Stukey  DMP  785-532-4621  mstukey@vet.k-state.edu 























B. Non-KSU Collaborators:  (List all collaborators on your human subjects research project not affiliated 
with KSU in the spaces below.  KSU has negotiated an Assurance with the Office for Human Research 
Protections (OHRP), the federal office responsible for oversight of research involving human subjects. 
When research involving human subjects includes collaborators who are not employees or agents of 
KSU the activities of those unaffiliated individuals may be covered under the KSU Assurance only in 
accordance with a formal, written agreement of commitment to relevant human subject protection 
policies and IRB oversight.  The Unaffiliated Investigators Agreement can be found and downloaded at 
http://www.k-state.edu/research/comply/irb/forms/Unaffiliated%20Investigator%20Agreement.doc 
C.  
 The URCO must have a copy of the Unaffiliated Investigator Agreement on file for each non-KSU 
collaborator who is not covered by their own IRB and assurance with OHRP.  Consequently, it is critical 
that you identify non-KSU collaborators, and initiate any coordination and/or approval process early, to 
minimize delays caused by administrative requirements.) 
   
Name:  Organization:  Phone:  Institutional Email: 
NA                      
                           
                           
                           
 
Does your non-KSU collaborator’s organization have an Assurance with OHRP? (for  Federalwide Assurance 
and Multiple Project Assurance (MPA) listings of other institutions, please reference the OHRP website under 
Assurance Information at: http://ohrp.cit.nih.gov/search). 
 No  
 Yes If yes, Collaborator’s FWA or MPA #       
  
 Is your non-KSU collaborator’s IRB reviewing this proposal? 
 No  
 Yes If yes, IRB approval #       
 
 C. Exempt Projects:  45 CFR 46 identifies six categories of research involving human subjects that may 
be exempt from IRB review.  The categories for exemption are listed here:  
http://www.hhs.gov/ohrp/policy/checklists/decisioncharts.html.  If you believe that your project 
qualifies for exemption, please indicate which exemption category applies (1-6).  Please remember that 
only the IRB can make the final determination whether a project is exempt from IRB review, or not. 
Exemption Category:       
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XIII.  CLINICAL TRIAL  Yes   No 
 (If so, please give product.)        
 
Export Controls Training:   
-The Provost has mandated that all KSU faculty/staff with a full-time appointment participate in the Export 
Control Program. 
-If you are not in our database as having completed the Export Control training, this proposal will not be 
approved until your participation is verified. 





 1. After signing into K-State Online, you will be taken to the Export Control Homepage 
 2. Read the directions and click on the video link to begin the program 
 3. Make sure you enter your name / email when prompted so that participation is verified 
 
If you click on the link and are not taken to K-State Online, this means that you have already 
completed the Export Control training and have been removed from the roster.  If this is the case, no 
further action is required. 
 
-Can’t recall if you have completed this training?  Contact the URCO at 785-532-3224 or comply@ksu.edu 
and we will be happy to look it up for you. 
 
 
Post Approval Monitoring:  The URCO has a Post-Approval Monitoring (PAM) program to help assure that 
activities are performed in accordance with provisions or procedures approved by the IRB.  Accordingly, the 




If you have questions, please call the University Research Compliance Office (URCO) at 532-3224, or comply@ksu.edu 
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INVESTIGATOR ASSURANCE FOR RESEARCH INVOLVING HUMAN SUBJECTS 
(Print this page separately because it requires a signature by the PI.) 
 
P.I. Name: Dr. M. M. Chengappa 
 
Title of Project: Cut-off Values for Rabies Serology Methods - Are They Interchangeable? 
 
XIV.  ASSURANCES:  As the Principal Investigator on this protocol, I provide assurances for the following: 
 
A. Research Involving Human Subjects:  This project will be performed in the manner described in 
this proposal, and in accordance with the Federalwide Assurance FWA00000865 approved for 
Kansas State University available at http://ohrp.osophs.dhhs.gov/polasur.htm#FWA, applicable 
laws, regulations, and guidelines.  Any proposed deviation or modification from the procedures 
detailed herein must be submitted to the IRB, and be approved by the Committee for Research 
Involving Human Subjects (IRB) prior to implementation. 
 
B. Training:  I assure that all personnel working with human subjects described in this protocol are 
technically competent for the role described for them, and have completed the required IRB 
training modules found on the URCO website at:   
http://www.k-state.edu/research/comply/irb/training/index.htm.   I understand that no proposals 
will receive final IRB approval until the URCO has documentation of completion of training by all 
appropriate personnel. 
 
C. Extramural Funding:  If funded by an extramural source, I assure that this application accurately 
reflects all procedures involving human subjects as described in the grant/contract proposal to the 
funding agency.  I also assure that I will notify the IRB/URCO, the KSU PreAward Services, and 
the funding/contract entity if there are modifications or changes made to the protocol after the 
initial submission to the funding agency. 
 
D. Study Duration: I understand that it is the responsibility of the Committee for Research Involving 
Human Subjects (IRB) to perform continuing reviews of human subjects research as necessary.  I 
also understand that as continuing reviews are conducted, it is my responsibility to provide timely 
and accurate review or update information when requested, to include notification of the 
IRB/URCO when my study is changed or completed. 
 
E. Conflict of Interest:  I assure that I have accurately described (in this application) any potential 
Conflict of Interest that my collaborators, the University, or I may have in association with this 
proposed research activity.  
 
F. Adverse Event Reporting: I assure that I will promptly report to the IRB / URCO any 
unanticipated problems involving risks to subjects or others that involve the protocol as approved. 
Unanticipated or Adverse Event Form is located on the URCO website at:                                                        
http://www.k-state.edu/research/comply/irb/forms/index.htm. In the case of a serious event, the 
Unanticipated or Adverse Events Form may follow a phone call or email contact with the URCO. 
 
G. Accuracy:  I assure that the information herein provided to the Committee for Human Subjects 




   
(Principal Investigator Signature)  (date) 
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APPENDIX C – USDA BIOLOGICAL PRODUCT PERMIT 
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Kansas State University 
College of Veterinary Medicine 
Department of Diagnostic Medicine/Pathobiology 




VALIDATING AND STANDARDIZATION OF THE 
SYNBIOTICS RABIES ELISA TEST, SERELISA® RABIES 
Ab MONO INDIRECT, FOR DETECTION OF ANTI-RABIES 
ANTIBODIES IN INDIVIDUAL HUMAN SERUM 
 
 
Prepared By: __________________________________   Date: _____________________ 
 Mylissia Smith, MPH Candidate Kansas State University 
 
Approved By: ___________________________________Date: ______________________ 
 Susan Moore, Managing Director of the KSVDL Rabies Laboratory 
 
Approved By: ___________________________________Date: ______________________ 
 Dr. Stephane Guillossou, Zoetis - Director, Global Diagnostics Marketing – US 
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This document has been prepared by and remains the property of the Kansas State 
Veterinary Diagnostic Laboratory.  It is submitted to a client or agency solely for its use in 
evaluating the Diagnostic Laboratory qualifications in connection with the particular 
project, certification or approval for which it was prepared. 
 
Appendix A - 1. INTRODUCTION  
Rabies testing methodologies allow for the evaluation of vaccine response levels to determine if 
individuals have adequate protection against the rabies virus.  The WHO recommends animal 
samples for export requirements and human samples previously vaccinated for rabies have a 
continuous antibody level response of 0.5 IU/mL to be considered adequate for an immune 
response to rabies (WHO, 2013).   The WHO recommendations are based off of the RFFIT or 
MNT serology testing methodology as these methodologies measure the level of rabies virus 
neutralizing antibodies (RVNA) (Moore, Hanlon, 2010).  This protocol is aimed to investigate 
the performance of a rabies ELISA testing methodology to determine adequate immune response 
levels to rabies vaccines.  The ELISA measures quantitative antibody levels in individual serum 
samples.  To date, the WHO does not have adequate recommendations for immune response 
levels for the ELISA testing methodology. 
 
Appendix B - 2. OBJECTIVE AND ACCEPTANCE CRITERIA 
2.1. Objective 
The objective of this protocol is dual.  The first objective will investigate the performances of 
this ELISA on human sample origin for the appreciation of the protection status obtained after 
Rabies vaccination.  The second parallel objective is to establish standardization curves and 
appreciate the robustness of the test when using different international reference sera (WHO-1, 
WHO-2, OIE and Kansas State University).   
2.2. Acceptance Criteria  
The ELISA allows for quantitative detection of rabies antibodies in individual serum.  Results 
of the ELISA samples are most precise when you obtain the results noted in section 6.2, Test 
Procedures, D of this document.         
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3. STUDY RATIONALE AND BACKGROUND INFORMATION 
The purpose of this study is to run a series of reference samples to validate the ELISA for 
appreciating the performances of the test and investigating if a different cut off is mandated for 
assessment of the antibody immune response status in human samples.  As aforementioned, the 
WHO 0.5 IU/mL recommended continuous antibody level for an immune response is based from 
the RFFIT testing methodology that measures RVNA.  More specifically an RVNA test 
measures only neutralizing antibody in the sample due to the nature of the test itself (Moore, 
Gordon, Briggs, 2007).  The ELISA testing methodology measures the binding of antibodies to 
the rabies virus antigen independently from the seroneutralizing property of the antibodies.  As a 
result, applying the WHO 0.5 IU/mL recommendation established upon seroneutralizing 
detection method to binding methods such as the ELISA might lead to different performances 
and therefore should be investigated.  
 
4. STUDY METHODOLOGY 
The Zoetis ELISA will be compared and evaluated again reference standards from the WHO, 
OIE and KSU.  Section 6.1 C outlines the titration and dilutions of each standard that will be 
utilized.  The first two ELISA microplates displayed in Section 6.1 E displays the layout of how 
each ELISA microplate will be prepared and tested.  Microplate three four displays the layout of 
how the microplates will be tested, which will consist of three series of human serum samples 
that will consist of the same titration and dilutions as specified in section 6.1 C.  Upon 
completion of each microplate, validation and expression of each test will be interpreted.   
 
 3.1 Test Validation  
The results of each test run (or for each plate) are validate: 
 A.  When the OD obtained with the positive control is ≥ 0.3000, and 
 B.  When the OD obtained with the negative control is < 0.50 x OD P, and 
 C.  When the correlation coefficient between the Neperian logarithm (ln) ODs                                 
and in Rabies Ab concentrations for the WHO standard serum is > 0.95.   
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3.2 Expression and Interpretation of the Results 
The method of titer calculation will be completed using the Regression Curve.  The calculations 
will be accomplished by utilizing an Excel spreadsheet obtained by Zoetis specifically designed 
for this ELISA.  Calculations will include: 
 
A.  Calculate the average OD value for each sample tested and each WHO serum dilution.  Also 
calculate OIE and KSU reference serum from the WHO standard curve.  Also compare results 
against each other. 
B.  Calculate the Neperian Logarithm (ln) value for each average OD and the ln                                  
Value of the Rabies Ab concentration for each WHO, KSU and OIE dilution. 
C.  Plot the ln (OD) (Y axis) as a function of the ln (Rabies Ab concentration)                                  
(X axis) in order to draw the reference curve for the WHO, KSU and OIE standard serum. 
D.  Use all individual results obtained for the WHO, KSU and OIE standard serum dilutions, 
perform a linear regression curve between ln Rabies Ab concentrations (expressed in EU/mL) 
(equivalent units per mL) and ln (OD), to establish the corresponding mathematics model:  
                                ln[Rabies Ab concentration (EU/mL)] = a + b * ln OD 
For each tested sample, calculate the average OD value and then the Rabies antibody 
concentration of the sample expressed as equivalent units per ml»                                (EU/mL), 
from the established model: Sample Rabies Ab concentration 
                                (EU/mL) = e 
(a   b  ln OD) 
 
 
E.  If the calculated titer is > 0.6, the sample is considered as protected, 
F.  If the calculated titer is < 0.6, the sample is considered as not protected (a confirmation 




5.1 Reagents  
Note: for all reagents record date opened and initials on the container upon first use.  Label 
secondary container for reagent dilution with Name, Concentration (Dilution), Date Made, 
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Expiration date (per original container or kit instructions), storage temperature, and initials. 
 
 Conjugate: Protein A / peroxidase (CJ) (10X concentrated) 
 Buffered peroxidase substrate (PS) – Ready-to-use 
 Negative control (N) (10X concentrated) 
 Positive control (P) (10X concentrated) 
 Sample diluent (SD) – Ready-to-use 
 Wash solution (W) (10X concentrated) 
 Conjugate diluent (CD) – Ready-to-use 
 Stop solution (S) – Ready-to-use 
 
5.2 Supplies Included In Kit 
Microplate containing six 16-well strips sensitized with Rabies Antigens                                                  
Adhesive film – 6 films 
 
5.3 Supplies Required & Not Included In Kit 
    
  5.3.1 Reference Sera 
 WHO Reference Serum – Obtained from NIBSC 
 WHO #1 – 59 IU/mL 
 WHO #2 – 30 IU/mL 
   
 OIE – 6.7 IU/mL, Batch #3 
 KSU Reference Serum  
 KSU from WHO #1 (59 IU/mL) 
 KSU Internal #1- 15.0 (Pooled from positive RVNA samples from a RFFIT set) 
 KSU Internal #2 – 2.8 (Pooled from positive RVNA samples from a RFFIT set) 
 KSU Internal #3 – 0.5 (Pooled from positive RVNA samples from a RFFIT set) 
 KSU Internal #4 – 0.1 (Pooled from positive RVNA samples from a RFFIT set) 
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5.3.2 Laboratory equipment 
 Distilled or demineralized water 
 Adjustable or set pipettes to measure and deliver between 0-1000µl. 
 Graduated cylinders (100mL and 1000mL) 
 Manual, automatic or semi-automatic washing device  
  Microplate reader, bichromatic reading at 450 & 630 nm.   
  Incubator at +37 ± 3°C 
   
6. METHOD SYNBIOTICS ELISA 
6.1 Preliminary Procedure 
 
A.  Set up distribution and identification of controls and samples. 
B.  Prepare the sera to be tested.  Dilutions are performed in the kit sample diluent (SD).  
Dilutions should be performed as indicated in the microplate tables below (microplates 
numbered 1-10). 
C.  For serum titration, a set of seven dilutions in duplicate of the WHO, OIE and KSU should be 
performed in the microplates as indicated in the microplate tables below (microplates numbered 
1-10).  
D.  For serum titration, a set of four KSU standard reference serums in duplicate should be 












    65 
 





A N 1:10 N 1:10 OIEa 1:30,000 OIEa 1:30,000 WHO1 1:300,000 WHO1 1:300,000 WHO2 1:150,000 WHO2 1:150,000 KSU 1:300,000 KSU 1:300,000 OIEa 1:30,000 OIEa 1:30,000
B P 1:10 P 1:10 KSU Ref#1 1:100 KSU Ref#1 1:100 KSU Ref#2 1:100 KSU Ref#2 1:100 KSU Ref#3 1:100 KSU Ref#3 1:100 KSU Ref#4 1:100 KSU Ref#4 1:100 WHO1 1:300,000 WHO1 1:300,000
C OIEa 1:100 OIEa 1:100 WHO1 1:1,000 WHO1 1:1,000 WHO2 1:500 WHO2 1:500 KSU 1:1,000 KSU 1:1,000 OIEa 1:100 OIEa 1:100 WHO1 1:1,000 WHO1 1:1,000
D OIEa 1:300 OIEa 1:300 WHO1 1:3,000 WHO1 1:3,000 WHO2 1:1,500 WHO2 1:1,500 KSU 1:3,000 KSU 1:3,000 OIEa 1:300 OIEa 1:300 WHO1 1:3,000 WHO1 1:3,000
E OIEa 1:1,000 OIEa 1:1,000 WHO1 1:10,000 WHO1 1:10,000 WHO2 1:5,000 WHO2 1:5,000 KSU 1:10,000 KSU 1:10,000 OIEa 1:1,000 OIEa 1:1,000 WHO1 1:10,000 WHO1 1:10,000
F OIEa 1:1,500 OIEa 1:1,500 WHO1 1:15,000 WHO1 1:15,000 WHO2 1:7,500 WHO2 1:7,500 KSU 1:15,000 KSU 1:15,000 OIEa 1:1,500 OIEa 1:1,500 WHO1 1:15,000 WHO1 1:15,000
G OIEa 1:3,000 OIEa 1:3,000 WHO1 1:30,000 WHO1 1:30,000 WHO2 1:15,000 WHO2 1:15,000 KSU 1:30,000 KSU 1:30,000 OIEa 1:3,000 OIEa 1:3,000 WHO1 1:30,000 WHO1 1:30,000
H OIEa 1:10,000 OIEa 1:10,000 WHO1 1:100,000 WHO1 1:100,000 WHO2 1:50,000 WHO2 1:50,000 KSU 1:100,000 KSU 1:100,000 OIEa 1:10,000 OIEa 1:10,000 WHO1 1:100,000 WHO1 1:100,000
1 2 3 4 5 6 7 8 9 10 11 12
A N 1:10 N 1:10 0.0223 IU/ml 0.0223 IU/ml 0.0197 IU/ml 0.0197 IU/ml 0.02 IU/ml 0.02 IU/ml 0.0197 IU/ml 0.0197 IU/ml 0.0223 IU/ml 0.0223 IU/ml
B P 1:10 P 1:10 15.0 IU/ml 15.0 IU/ml 2.8 IU/ml 2.8 IU/ml 0.5 IU/ml 0.5 IU/ml 0.1 IU/ml 0.1 IU/ml 0.0197 IU/ml 0.0197 IU/ml
C 6.7 IU/ml 6.7 IU/ml 5.9 IU/ml 5.9 IU/ml 6 IU/ml 6 IU/ml 5.9 IU/ml 5.9 IU/ml 6.7 IU/ml 6.7 IU/ml 5.9 IU/ml 5.9 IU/ml
D 2.23 IU/ml 2.23 IU/ml 1.97 IU/ml 1.97 IU/ml 2 IU/ml 2 IU/ml 1.97 IU/ml 1.97 IU/ml 2.23 IU/ml 2.23 IU/ml 1.97 IU/ml 1.97 IU/ml
E 0.67 IU/ml 0.67 IU/ml 0.59 IU/ml 0.59 IU/ml 0.6 IU/ml 0.6 IU/ml 0.59 IU/ml 0.59 IU/ml 0.67 IU/ml 0.67 IU/ml 0.59 IU/ml 0.59 IU/ml
F 0.447 IU/ml 0.447 IU/ml 0.39 IU/ml 0.39 IU/ml 0.4 IU/ml 0.4 IU/ml 0.39 IU/ml 0.39 IU/ml 0.447 IU/ml 0.447 IU/ml 0.39 IU/ml 0.39 IU/ml
G 0.223 IU/ml 0.223 IU/ml 0.197 IU/ml 0.197 IU/ml 0.2 IU/ml 0.2 IU/ml 0.197 IU/ml 0.197 IU/ml 0.223 IU/ml 0.223 IU/ml 0.197 IU/ml 0.197 IU/ml
H 0.067 IU/ml 0.067 IU/ml 0.059 IU/ml 0.059 IU/ml 0.06 IU/ml 0.06 IU/ml 0.059 IU/ml 0.059 IU/ml 0.067 IU/ml 0.067 IU/ml 0.059 IU/ml 0.059 IU/ml
A N 1:10 N 1:10 OIEa 1:30,000 OIEa 1:30,000 WHO1 1:300,000 WHO1 1:300,000 WHO2 1:150,000 WHO2 1:150,000 KSU 1:300,000 KSU 1:300,000 WHO2 1:150,000 WHO2 1:150,000
B P 1:10 P 1:10 KSU Ref#1 1:100 KSU Ref#1 1:100 KSU Ref#2 1:100 KSU Ref#2 1:100 KSU Ref#3 1:100 KSU Ref#3 1:100 KSU Ref#4 1:100 KSU Ref#4 1:100 KSU 1:300,000 KSU 1:300,000
C OIEa 1:100 OIEa 1:100 WHO1 1:1,000 WHO1 1:1,000 WHO2 1:500 WHO2 1:500 KSU 1:1,000 KSU 1:1,000 WHO2 1:500 WHO2 1:500 KSU 1:1,000 KSU 1:1,000
D OIEa 1:300 OIEa 1:300 WHO1 1:3,000 WHO1 1:3,000 WHO2 1:1,500 WHO2 1:1,500 KSU 1:3,000 KSU 1:3,000 WHO2 1:1,500 WHO2 1:1,500 KSU 1:3,000 KSU 1:3,000
E OIEa 1:1,000 OIEa 1:1,000 WHO1 1:10,000 WHO1 1:10,000 WHO2 1:5,000 WHO2 1:5,000 KSU 1:10,000 KSU 1:10,000 WHO2 1:5,000 WHO2 1:5,000 KSU 1:10,000 KSU 1:10,000
F OIEa 1:1,500 OIEa 1:1,500 WHO1 1:15,000 WHO1 1:15,000 WHO2 1:7,500 WHO2 1:7,500 KSU 1:15,000 KSU 1:15,000 WHO2 1:7,500 WHO2 1:7,500 KSU 1:15,000 KSU 1:15,000
G OIEa 1:3,000 OIEa 1:3,000 WHO1 1:30,000 WHO1 1:30,000 WHO2 1:15,000 WHO2 1:15,000 KSU 1:30,000 KSU 1:30,000 WHO2 1:15,000 WHO2 1:15,000 KSU 1:30,000 KSU 1:30,000
H OIEa 1:10,000 OIEa 1:10,000 WHO1 1:100,000 WHO1 1:100,000 WHO2 1:50,000 WHO2 1:50,000 KSU 1:100,000 KSU 1:100,000 WHO2 1:50,000 WHO2 1:50,000 KSU 1:100,000 KSU 1:100,000
1 2 3 4 5 6 7 8 9 10 11 12
A N 1:10 N 1:10 0.0223 IU/ml 0.0223 IU/ml 0.0197 IU/ml 0.0197 IU/ml 0.02 IU/ml 0.02 IU/ml 0.0197 IU/ml 0.0197 IU/ml 0.02 IU/ml 0.02 IU/ml
B P 1:10 P 1:10 15.0 IU/ml 15.0 IU/ml 2.8 IU/ml 2.8 IU/ml 0.5 IU/ml 0.5 IU/ml 0.1 IU/ml 0.1 IU/ml 0.0197 IU/ml 0.0197 IU/ml
C 6.7 IU/ml 6.7 IU/ml 5.9 IU/ml 5.9 IU/ml 6 IU/ml 6 IU/ml 5.9 IU/ml 5.9 IU/ml 6 IU/ml 6 IU/ml 5.9 IU/ml 5.9 IU/ml
D 2.23 IU/ml 2.23 IU/ml 1.97 IU/ml 1.97 IU/ml 2 IU/ml 2 IU/ml 1.97 IU/ml 1.97 IU/ml 2 IU/ml 2 IU/ml 1.97 IU/ml 1.97 IU/ml
E 0.67 IU/ml 0.67 IU/ml 0.59 IU/ml 0.59 IU/ml 0.6 IU/ml 0.6 IU/ml 0.59 IU/ml 0.59 IU/ml 0.6 IU/ml 0.6 IU/ml 0.59 IU/ml 0.59 IU/ml
F 0.447 IU/ml 0.447 IU/ml 0.39 IU/ml 0.39 IU/ml 0.4 IU/ml 0.4 IU/ml 0.39 IU/ml 0.39 IU/ml 0.4 IU/ml 0.4 IU/ml 0.39 IU/ml 0.39 IU/ml
G 0.223 IU/ml 0.223 IU/ml 0.197 IU/ml 0.197 IU/ml 0.2 IU/ml 0.2 IU/ml 0.197 IU/ml 0.197 IU/ml 0.2 IU/ml 0.2 IU/ml 0.197 IU/ml 0.197 IU/ml
H 0.067 IU/ml 0.067 IU/ml 0.059 IU/ml 0.059 IU/ml 0.06 IU/ml 0.06 IU/ml 0.059 IU/ml 0.059 IU/ml 0.06 IU/ml 0.06 IU/ml 0.059 IU/ml 0.059 IU/ml









A N 1:10 N 1:10 OIEa 1:30,000 OIEa 1:30,000 WHO1 1:300,000 WHO1 1:300,000 WHO2 1:150,000 WHO2 1:150,000 KSU 1:300,000 KSU 1:300,000 OIEa 1:30,000 OIEa 1:30,000
B P 1:10 P 1:10 KSU Ref#1 1:100 KSU Ref#1 1:100 KSU Ref#2 1:100 KSU Ref#2 1:100 KSU Ref#3 1:100 KSU Ref#3 1:100 KSU Ref#4 1:100 KSU Ref#4 1:100 WHO2 1:150,000 WHO2 1:150,000
C OIEa 1:100 OIEa 1:100 WHO1 1:1,000 WHO1 1:1,000 WHO2 1:500 WHO2 1:500 KSU 1:1,000 KSU 1:1,000 OIEa 1:100 OIEa 1:100 WHO2 1:500 WHO2 1:500
D OIEa 1:300 OIEa 1:300 WHO1 1:3,000 WHO1 1:3,000 WHO2 1:1,500 WHO2 1:1,500 KSU 1:3,000 KSU 1:3,000 OIEa 1:300 OIEa 1:300 WHO2 1:1,500 WHO2 1:1,500
E OIEa 1:1,000 OIEa 1:1,000 WHO1 1:10,000 WHO1 1:10,000 WHO2 1:5,000 WHO2 1:5,000 KSU 1:10,000 KSU 1:10,000 OIEa 1:1,000 OIEa 1:1,000 WHO2 1:5,000 WHO2 1:5,000
F OIEa 1:1,500 OIEa 1:1,500 WHO1 1:15,000 WHO1 1:15,000 WHO2 1:7,500 WHO2 1:7,500 KSU 1:15,000 KSU 1:15,000 OIEa 1:1,500 OIEa 1:1,500 WHO2 1:7,500 WHO2 1:7,500
G OIEa 1:3,000 OIEa 1:3,000 WHO1 1:30,000 WHO1 1:30,000 WHO2 1:15,000 WHO2 1:15,000 KSU 1:30,000 KSU 1:30,000 OIEa 1:3,000 OIEa 1:3,000 WHO2 1:15,000 WHO2 1:15,000
H OIEa 1:10,000 OIEa 1:10,000 WHO1 1:100,000 WHO1 1:100,000 WHO2 1:50,000 WHO2 1:50,000 KSU 1:100,000 KSU 1:100,000 OIEa 1:10,000 OIEa 1:10,000 WHO2 1:50,000 WHO2 1:50,000
1 2 3 4 5 6 7 8 9 10 11 12
A N 1:10 N 1:10 0.0223 IU/ml 0.0223 IU/ml 0.0197 IU/ml 0.0197 IU/ml 0.02 IU/ml 0.02 IU/ml 0.0197 IU/ml 0.0197 IU/ml 0.0223 IU/ml 0.0223 IU/ml
B P 1:10 P 1:10 15.0 IU/ml 15.0 IU/ml 2.8 IU/ml 2.8 IU/ml 0.5 IU/ml 0.5 IU/ml 0.1 IU/ml 0.1 IU/ml 0.02 IU/ml 0.02 IU/ml
C 6.7 IU/ml 6.7 IU/ml 5.9 IU/ml 5.9 IU/ml 6 IU/ml 6 IU/ml 5.9 IU/ml 5.9 IU/ml 6.7 IU/ml 6.7 IU/ml 6 IU/ml 6 IU/ml
D 2.23 IU/ml 2.23 IU/ml 1.97 IU/ml 1.97 IU/ml 2 IU/ml 2 IU/ml 1.97 IU/ml 1.97 IU/ml 2.23 IU/ml 2.23 IU/ml 2 IU/ml 2 IU/ml
E 0.67 IU/ml 0.67 IU/ml 0.59 IU/ml 0.59 IU/ml 0.6 IU/ml 0.6 IU/ml 0.59 IU/ml 0.59 IU/ml 0.67 IU/ml 0.67 IU/ml 0.6 IU/ml 0.6 IU/ml
F 0.447 IU/ml 0.447 IU/ml 0.39 IU/ml 0.39 IU/ml 0.4 IU/ml 0.4 IU/ml 0.39 IU/ml 0.39 IU/ml 0.447 IU/ml 0.447 IU/ml 0.4 IU/ml 0.4 IU/ml
G 0.223 IU/ml 0.223 IU/ml 0.197 IU/ml 0.197 IU/ml 0.2 IU/ml 0.2 IU/ml 0.197 IU/ml 0.197 IU/ml 0.223 IU/ml 0.223 IU/ml 0.2 IU/ml 0.2 IU/ml
H 0.067 IU/ml 0.067 IU/ml 0.059 IU/ml 0.059 IU/ml 0.06 IU/ml 0.06 IU/ml 0.059 IU/ml 0.059 IU/ml 0.067 IU/ml 0.067 IU/ml 0.06 IU/ml 0.06 IU/ml
A N 1:10 N 1:10 OIEa 1:30,000 OIEa 1:30,000 WHO1 1:300,000 WHO1 1:300,000 WHO2 1:150,000 WHO2 1:150,000 KSU 1:300,000 KSU 1:300,000 WHO1 1:300,000 WHO1 1:300,000
B P 1:10 P 1:10 KSU Ref#1 1:100 KSU Ref#1 1:100 KSU Ref#2 1:100 KSU Ref#2 1:100 KSU Ref#3 1:100 KSU Ref#3 1:100 KSU Ref#4 1:100 KSU Ref#4 1:100 KSU 1:300,000 KSU 1:300,000
C OIEa 1:100 OIEa 1:100 WHO1 1:1,000 WHO1 1:1,000 WHO2 1:500 WHO2 1:500 KSU 1:1,000 KSU 1:1,000 WHO1 1:1,000 WHO1 1:1,000 KSU 1:1,000 KSU 1:1,000
D OIEa 1:300 OIEa 1:300 WHO1 1:3,000 WHO1 1:3,000 WHO2 1:1,500 WHO2 1:1,500 KSU 1:3,000 KSU 1:3,000 WHO1 1:3,000 WHO1 1:3,000 KSU 1:3,000 KSU 1:3,000
E OIEa 1:1,000 OIEa 1:1,000 WHO1 1:10,000 WHO1 1:10,000 WHO2 1:5,000 WHO2 1:5,000 KSU 1:10,000 KSU 1:10,000 WHO1 1:10,000 WHO1 1:10,000 KSU 1:10,000 KSU 1:10,000
F OIEa 1:1,500 OIEa 1:1,500 WHO1 1:15,000 WHO1 1:15,000 WHO2 1:7,500 WHO2 1:7,500 KSU 1:15,000 KSU 1:15,000 WHO1 1:15,000 WHO1 1:15,000 KSU 1:15,000 KSU 1:15,000
G OIEa 1:3,000 OIEa 1:3,000 WHO1 1:30,000 WHO1 1:30,000 WHO2 1:15,000 WHO2 1:15,000 KSU 1:30,000 KSU 1:30,000 WHO1 1:30,000 WHO1 1:30,000 KSU 1:30,000 KSU 1:30,000
H OIEa 1:10,000 OIEa 1:10,000 WHO1 1:100,000 WHO1 1:100,000 WHO2 1:50,000 WHO2 1:50,000 KSU 1:100,000 KSU 1:100,000 WHO1 1:100,000 WHO1 1:100,000 KSU 1:100,000 KSU 1:100,000
1 2 3 4 5 6 7 8 9 10 11 12
A N 1:10 N 1:10 0.0223 IU/ml 0.0223 IU/ml 0.0197 IU/ml 0.0197 IU/ml 0.02 IU/ml 0.02 IU/ml 0.0197 IU/ml 0.0197 IU/ml 0.0197 IU/ml 0.0197 IU/ml
B P 1:10 P 1:10 15.0 IU/ml 15.0 IU/ml 2.8 IU/ml 2.8 IU/ml 0.5 IU/ml 0.5 IU/ml 0.1 IU/ml 0.1 IU/ml 0.0197 IU/ml 0.0197 IU/ml
C 6.7 IU/ml 6.7 IU/ml 5.9 IU/ml 5.9 IU/ml 6 IU/ml 6 IU/ml 5.9 IU/ml 5.9 IU/ml 5.9 IU/ml 5.9 IU/ml 5.9 IU/ml 5.9 IU/ml
D 2.23 IU/ml 2.23 IU/ml 1.97 IU/ml 1.97 IU/ml 2 IU/ml 2 IU/ml 1.97 IU/ml 1.97 IU/ml 1.97 IU/ml 1.97 IU/ml 1.97 IU/ml 1.97 IU/ml
E 0.67 IU/ml 0.67 IU/ml 0.59 IU/ml 0.59 IU/ml 0.6 IU/ml 0.6 IU/ml 0.59 IU/ml 0.59 IU/ml 0.59 IU/ml 0.59 IU/ml 0.59 IU/ml 0.59 IU/ml
F 0.447 IU/ml 0.447 IU/ml 0.39 IU/ml 0.39 IU/ml 0.4 IU/ml 0.4 IU/ml 0.39 IU/ml 0.39 IU/ml 0.39 IU/ml 0.39 IU/ml 0.39 IU/ml 0.39 IU/ml
G 0.223 IU/ml 0.223 IU/ml 0.197 IU/ml 0.197 IU/ml 0.2 IU/ml 0.2 IU/ml 0.197 IU/ml 0.197 IU/ml 0.197 IU/ml 0.197 IU/ml 0.197 IU/ml 0.197 IU/ml
H 0.067 IU/ml 0.067 IU/ml 0.059 IU/ml 0.059 IU/ml 0.06 IU/ml 0.06 IU/ml 0.059 IU/ml 0.059 IU/ml 0.059 IU/ml 0.059 IU/ml 0.059 IU/ml 0.059 IU/ml











A N 1:10 N 1:10 WHO1 1:300,000 WHO1 1:300,000 S4 1:100 S4 1:100 S12 1:100 S12 1:100 S20 1:100 S20 1:100 S28 1:100 S28 1:100
B P 1:10 P 1:10 KSU Ref#1 1:100 KSU Ref#1 1:100 S5 1:100 S5 1:100 S13 1:100 S13 1:100 S21 1:100 S21 1:100 S29 1:100 S29 1:100
C WHO1 1:1,000 WHO1 1:1,000 KSU Ref#2 1:100 KSU Ref#2 1:100 S6 1:100 S6 1:100 S14 1:100 S14 1:100 S22 1:100 S22 1:100 S30 1:100 S30 1:100
D WHO1 1:3,000 WHO1 1:3,000 KSU Ref#3 1:100 KSU Ref#3 1:100 S7 1:100 S7 1:100 S15 1:100 S15 1:100 S23 1:100 S23 1:100 S31 1:100 S31 1:100
E WHO1 1:10,000 WHO1 1:10,000 KSU Ref#4 1:100 KSU Ref#4 1:100 S8 1:100 S8 1:100 S16 1:100 S16 1:100 S24 1:100 S24 1:100 S32 1:100 S32 1:100
F WHO1 1:15,000 WHO1 1:15,000 S1 1:100 S1 1:100 S9 1:100 S9 1:100 S17 1:100 S17 1:100 S25 1:100 S25 1:100 S33 1:100 S33 1:100
G WHO1 1:30,000 WHO1 1:30,000 S2 1:100 S2 1:100 S10 1:100 S10 1:100 S18 1:100 S18 1:100 S26 1:100 S26 1:100 S34 1:100 S34 1:100
H WHO1 1:100,000 WHO1 1:100,000 S3 1:100 S3 1:100 S11 1:100 S11 1:100 S19 1:100 S19 1:100 S27 1:100 S27 1:100 S35 1:100 S35 1:100
1 2 3 4 5 6 7 8 9 10 11 12
A N 1:10 N 1:10 0.0197 IU/ml 0.0197 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
B P 1:10 P 1:10 15.0 IU/ml 15.0 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
C 5.9 IU/ml 5.9 IU/ml 2.8 IU/ml 2.8 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
D 1.97 IU/ml 1.97 IU/ml 0.5 IU/ml 0.5 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
E 0.59 IU/ml 0.59 IU/ml 0.1 IU/ml 0.1 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
F 0.39 IU/ml 0.39 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
G 0.197 IU/ml 0.197 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
H 0.059 IU/ml 0.059 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
A N 1:10 N 1:10 WHO1 1:300,000 WHO1 1:300,000 S39 1:100 S39 1:100 S47 1:100 S47 1:100 S55 1:100 S55 1:100 S63 1:100 S63 1:100
B P 1:10 P 1:10 KSU Ref#1 1:100 KSU Ref#1 1:100 S40 1:100 S40 1:100 S48 1:100 S48 1:100 S56 1:100 S56 1:100 S64 1:100 S64 1:100
C WHO1 1:1,000 WHO1 1:1,000 KSU Ref#2 1:100 KSU Ref#2 1:100 S41 1:100 S41 1:100 S49 1:100 S49 1:100 S57 1:100 S57 1:100 S65 1:100 S65 1:100
D WHO1 1:3,000 WHO1 1:3,000 KSU Ref#3 1:100 KSU Ref#3 1:100 S42 1:100 S42 1:100 S50 1:100 S50 1:100 S58 1:100 S58 1:100 S66 1:100 S66 1:100
E WHO1 1:10,000 WHO1 1:10,000 KSU Ref#4 1:100 KSU Ref#4 1:100 S43 1:100 S43 1:100 S51 1:100 S51 1:100 S59 1:100 S59 1:100 S67 1:100 S67 1:100
F WHO1 1:15,000 WHO1 1:15,000 S36 1:100 S36 1:100 S44 1:100 S44 1:100 S52 1:100 S52 1:100 S60 1:100 S60 1:100 S68 1:100 S68 1:100
G WHO1 1:30,000 WHO1 1:30,000 S37 1:100 S37 1:100 S45 1:100 S45 1:100 S53 1:100 S53 1:100 S61 1:100 S61 1:100 S69 1:100 S69 1:100
H WHO1 1:100,000 WHO1 1:100,000 S38 1:100 S38 1:100 S46 1:100 S46 1:100 S54 1:100 S54 1:100 S62 1:100 S62 1:100 S70 1:100 S70 1:100
1 2 3 4 5 6 7 8 9 10 11 12
A N 1:10 N 1:10 0.0197 IU/ml 0.0197 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
B P 1:10 P 1:10 15.0 IU/ml 15.0 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
C 5.9 IU/ml 5.9 IU/ml 2.8 IU/ml 2.8 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
D 1.97 IU/ml 1.97 IU/ml 0.5 IU/ml 0.5 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
E 0.59 IU/ml 0.59 IU/ml 0.1 IU/ml 0.1 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
F 0.39 IU/ml 0.39 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
G 0.197 IU/ml 0.197 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
H 0.059 IU/ml 0.059 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown










A N 1:10 N 1:10 WHO1 1:300,000 WHO1 1:300,000 S74 1:100 S74 1:100 S82 1:100 S82 1:100 S90 1:100 S90 1:100 S98 1:100 S98 1:100
B P 1:10 P 1:10 KSU Ref#1 1:100 KSU Ref#1 1:100 S75 1:100 S75 1:100 S83 1:100 S83 1:100 S91 1:100 S91 1:100 S99 1:100 S99 1:100
C WHO1 1:1,000 WHO1 1:1,000 KSU Ref#2 1:100 KSU Ref#2 1:100 S76 1:100 S76 1:100 S84 1:100 S84 1:100 S92 1:100 S92 1:100 S100 1:100 S100 1:100
D WHO1 1:3,000 WHO1 1:3,000 KSU Ref#3 1:100 KSU Ref#3 1:100 S77 1:100 S77 1:100 S85 1:100 S85 1:100 S93 1:100 S93 1:100 S101 1:100 S101 1:100
E WHO1 1:10,000 WHO1 1:10,000 KSU Ref#4 1:100 KSU Ref#4 1:100 S78 1:100 S78 1:100 S86 1:100 S86 1:100 S94 1:100 S94 1:100 S102 1:100 S102 1:100
F WHO1 1:15,000 WHO1 1:15,000 S71 1:100 S71 1:100 S79 1:100 S79 1:100 S87 1:100 S87 1:100 S95 1:100 S95 1:100 S103 1:100 S103 1:100
G WHO1 1:30,000 WHO1 1:30,000 S72 1:100 S72 1:100 S80 1:100 S80 1:100 S88 1:100 S88 1:100 S96 1:100 S96 1:100 S104 1:100 S104 1:100
H WHO1 1:100,000 WHO1 1:100,000 S73 1:100 S73 1:100 S81 1:100 S81 1:100 S89 1:100 S89 1:100 S97 1:100 S97 1:100 S105 1:100 S105 1:100
1 2 3 4 5 6 7 8 9 10 11 12
A N 1:10 N 1:10 0.0197 IU/ml 0.0197 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
B P 1:10 P 1:10 15.0 IU/ml 15.0 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
C 5.9 IU/ml 5.9 IU/ml 2.8 IU/ml 2.8 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
D 1.97 IU/ml 1.97 IU/ml 0.5 IU/ml 0.5 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
E 0.59 IU/ml 0.59 IU/ml 0.1 IU/ml 0.1 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
F 0.39 IU/ml 0.39 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
G 0.197 IU/ml 0.197 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
H 0.059 IU/ml 0.059 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
A N 1:10 N 1:10 WHO1 1:300,000 WHO1 1:300,000 S109 1:100 S109 1:100 S117 1:100 S117 1:100 S125 1:100 S125 1:100 S133 1:100 S133 1:100
B P 1:10 P 1:10 KSU Ref#1 1:100 KSU Ref#1 1:100 S110 1:100 S110 1:100 S118 1:100 S118 1:100 S126 1:100 S126 1:100 S134 1:100 S134 1:100
C WHO1 1:1,000 WHO1 1:1,000 KSU Ref#2 1:100 KSU Ref#2 1:100 S111 1:100 S111 1:100 S119 1:100 S119 1:100 S127 1:100 S127 1:100 S135 1:100 S135 1:100
D WHO1 1:3,000 WHO1 1:3,000 KSU Ref#3 1:100 KSU Ref#3 1:100 S112 1:100 S112 1:100 S120 1:100 S120 1:100 S128 1:100 S128 1:100 S136 1:100 S136 1:100
E WHO1 1:10,000 WHO1 1:10,000 KSU Ref#4 1:100 KSU Ref#4 1:100 S113 1:100 S113 1:100 S121 1:100 S121 1:100 S129 1:100 S129 1:100 S137 1:100 S137 1:100
F WHO1 1:15,000 WHO1 1:15,000 S106 1:100 S106 1:100 S114 1:100 S114 1:100 S122 1:100 S122 1:100 S130 1:100 S130 1:100 S138 1:100 S138 1:100
G WHO1 1:30,000 WHO1 1:30,000 S107 1:100 S107 1:100 S115 1:100 S115 1:100 S123 1:100 S123 1:100 S131 1:100 S131 1:100 S139 1:100 S139 1:100
H WHO1 1:100,000 WHO1 1:100,000 S108 1:100 S108 1:100 S116 1:100 S116 1:100 S124 1:100 S124 1:100 S132 1:100 S132 1:100 S140 1:100 S140 1:100
1 2 3 4 5 6 7 8 9 10 11 12
A N 1:10 N 1:10 0.0197 IU/ml 0.0197 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
B P 1:10 P 1:10 15.0 IU/ml 15.0 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
C 5.9 IU/ml 5.9 IU/ml 2.8 IU/ml 2.8 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
D 1.97 IU/ml 1.97 IU/ml 0.5 IU/ml 0.5 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
E 0.59 IU/ml 0.59 IU/ml 0.1 IU/ml 0.1 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
F 0.39 IU/ml 0.39 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
G 0.197 IU/ml 0.197 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
H 0.059 IU/ml 0.059 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown









A N 1:10 N 1:10 WHO1 1:300,000 WHO1 1:300,000 S144 1:100 S144 1:100 S152 1:100 S152 1:100 S160 1:100 S160 1:100 S168 1:100 S168 1:100
B P 1:10 P 1:10 KSU Ref#1 1:100 KSU Ref#1 1:100 S145 1:100 S145 1:100 S153 1:100 S153 1:100 S161 1:100 S161 1:100 S169 1:100 S169 1:100
C WHO1 1:1,000 WHO1 1:1,000 KSU Ref#2 1:100 KSU Ref#2 1:100 S146 1:100 S146 1:100 S154 1:100 S154 1:100 S162 1:100 S162 1:100 S170 1:100 S171 1:100
D WHO1 1:3,000 WHO1 1:3,000 KSU Ref#3 1:100 KSU Ref#3 1:100 S147 1:100 S147 1:100 S155 1:100 S155 1:100 S163 1:100 S163 1:100 S172 1:100 S172 1:100
E WHO1 1:10,000 WHO1 1:10,000 KSU Ref#4 1:100 KSU Ref#4 1:100 S148 1:100 S148 1:100 S156 1:100 S156 1:100 S164 1:100 S164 1:100 S173 1:100 S173 1:100
F WHO1 1:15,000 WHO1 1:15,000 S141 1:100 S141 1:100 S149 1:100 S149 1:100 S157 1:100 S157 1:100 S165 1:100 S165 1:100 S174 1:100 S174 1:100
G WHO1 1:30,000 WHO1 1:30,000 S142 1:100 S142 1:100 S150 1:100 S150 1:100 S158 1:100 S158 1:100 S166 1:100 S166 1:100 S175 1:100 S175 1:100
H WHO1 1:100,000 WHO1 1:100,000 S143 1:100 S143 1:100 S151 1:100 S151 1:100 S159 1:100 S159 1:100 S167 1:100 S167 1:100 S176 1:100 S177 1:100
1 2 3 4 5 6 7 8 9 10 11 12
A N 1:10 N 1:10 0.0197 IU/ml 0.0197 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
B P 1:10 P 1:10 15.0 IU/ml 15.0 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
C 5.9 IU/ml 5.9 IU/ml 2.8 IU/ml 2.8 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
D 1.97 IU/ml 1.97 IU/ml 0.5 IU/ml 0.5 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
E 0.59 IU/ml 0.59 IU/ml 0.1 IU/ml 0.1 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown
F 0.39 IU/ml 0.39 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
G 0.197 IU/ml 0.197 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
H 0.059 IU/ml 0.059 IU/ml unknown unknown unknown unknown unknown unknown unknown unknown unknown unknown
A N 1:10 N 1:10 WHO1 1:300,000 WHO1 1:300,000 S179 1:100 S179 1:100
B P 1:10 P 1:10 KSU Ref#1 1:100 KSU Ref#1 1:100 S180 1:100 S180 1:100
C WHO1 1:1,000 WHO1 1:1,000 KSU Ref#2 1:100 KSU Ref#2 1:100
D WHO1 1:3,000 WHO1 1:3,000 KSU Ref#3 1:100 KSU Ref#3 1:100
E WHO1 1:10,000 WHO1 1:10,000 KSU Ref#4 1:100 KSU Ref#4 1:100
F WHO1 1:15,000 WHO1 1:15,000 S176 1:100 S176 1:100
G WHO1 1:30,000 WHO1 1:30,000 S177 1:100 S177 1:100
H WHO1 1:100,000 WHO1 1:100,000 S178 1:100 S178 1:100
1 2 3 4 5 6 7 8 9 10 11 12
A N 1:10 N 1:10 0.0197 IU/ml 0.0197 IU/ml unknown unknown
B P 1:10 P 1:10 15.0 IU/ml 15.0 IU/ml unknown unknown
C 5.9 IU/ml 5.9 IU/ml 2.8 IU/ml 2.8 IU/ml
D 1.97 IU/ml 1.97 IU/ml 0.5 IU/ml 0.5 IU/ml
E 0.59 IU/ml 0.59 IU/ml 0.1 IU/ml 0.1 IU/ml
F 0.39 IU/ml 0.39 IU/ml unknown unknown
G 0.197 IU/ml 0.197 IU/ml unknown unknown
H 0.059 IU/ml 0.059 IU/ml unknown unknown
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6.2 Test Procedure 
A.  Controls, References and Serum Distribution 
      1.  Control Distribution: 
      Controls are not ready-to-use and should be diluted at 1:10.  Dispense 90µl of sample diluent, 
and add 10µl of the kit negative control into wells A1 and A2, and 10µl of the positive control to 
wells B1 and B2. 
       2. Distribution of References and Serum: 
       Dispense 90µl of sample diluent, and add 10µl of either reference or serum        sample into 
the test wells and mix gently.  Strips should always be placed on the frame so that both washer 
and reader can be used.  Cover the wells with adhesive film, cut to the necessary length by the 
number of strips used.  Mix plate manually by gentle shaking or by using plate agitator. 
       3.  Incubation of the plate: 1 hour ± 5 minutes at +37 ± 3°C 
       4.  Plate Washing: Wash buffer: dilute the concentrated washing solution (W) 
       1:10 in distilled or demineralized water.  Carefully remove the adhesive film       and wash 4 
times. 
 
B.   Addition of the Conjugate 
       1.  Preparation of the conjugate: Dilute the concentrate (CJ) 1:10 in the conjugate diluent 
(CD). 2mL are needed for one strip, meaning 200µl of CJ in 1.8 mL of CD. 
       2.  Distribution of the Conjugate: Add 100µl of diluted conjugate to all the wells and cover 
with a new piece of adhesive film. 
       3.  Incubation of Conjugate: 1 hour ± 5 minutes at +37 ± 3°C  
       4.  Plate Washing: Carefully remove the adhesive film and wash 4 times. 
 
 
C.   Revelation  
       1.  Addition of the Substrate: Add 100µl of buffered peroxidase substrate (PS)  
 
per well.  Do not cover with adhesive film at this stage.  Mix by gentle shaking the plate 
manually or use a plate agitator to ensure correct homogenization. 
      2.  Incubation of substrate: Incubate for 30 ± 5 minutes at laboratory temperature (+23 ± 5°C) 
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shielded from light. 
      3.  Addition of the Stop Solution: Add 50µl of stop solution (S) per well.                                    
Mix by gentle shaking the plate manually or by using a plate agitator.  Make certain that no 
bubbles occur in the wells. 
      4.  Measure of the Optical Density: Measure the optical density (OD) bichromatically at 450 
and 630 nm or monochromatically at 450 nm (in the yellow band).  Reading bichromatically is 
strongly recommended.  Should a                                    monochromatic reader be used, ensure 
the cleanliness of the bottom of the wells prior to reading. 
 
D.   Test Validation 
The results of each test run (or for each plate) are validate: 
 A.  When the OD obtained with the positive control is ≥ 0.3000, and  
 B.  When the OD obtained with the negative control is < 0.50 x OD P, and 
 C.  When the correlation coefficient between the Neperian logarithm (ln) ODs                                 
and in Rabies Ab concentrations for the WHO standard serum is > 0.95. 
 
E.   Expression and Interpretation of the Results    
The method of titer calculation will be completed using the Regression                                
Curve.  The calculations will be accomplished by utilizing an Excel spread-                             
sheet obtained by Zoetis specifically designed for this ELISA.  Calculations                                
will include: 
       1.  Calculate the average OD value for each sample tested and each WHO                                  
serum dilution.  Also calculate OIE and KSU reference serum from the           WHO standard 
curve.  Also compare results against each other. 
         2.  Calculate the Neperian Logarithm (ln) value for each average OD and the ln Value of 
the Rabies Ab concentration for each WHO, KSU and OIE dilution. 
          3.  Plot the ln (OD) (Y axis) as a function of the ln (Rabies Ab concentration) (X axis) in 
order to draw the reference curve for the WHO, KSU and OIE standard serum. 
          4.  Use all individual results obtained for the WHO, KSU and OIE standard serum 
dilutions, perform a linear regression curve between ln Rabies Ab concentrations (expressed in 
EU/mL) (equivalent units per mL) and ln (OD), to establish the corresponding mathematics 
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model:  
                    ln[Rabies Ab concentration (EU/mL)] = a + b * ln OD 
For each tested sample, calculate the average OD value and then the Rabies                           
antibody concentration of the sample expressed as: 
«equivalent units per ml» (EU/mL), from the established model: Sample Rabies Ab 
concentration (EU/mL) = e 
(a   b  ln OD) 
               
5.  If the calculated titer is > 0.6, the sample is considered as protected. 
 
         6.  If the calculated titer is < 0.6, the sample is considered as not protected (a confirmation 




ELISA – Enzyme-linked Immunosorbent Assay 
KSU – Kansas State University 
OIE – World Organization For Animal Health 
MNT – Mouse Neutralizing Test 
PPE – Proper Protective Equipment 
RFFIT – Rapid Fluorescent Focus Inhibition Test 
RVNA – Rabies Virus Neutralizing Antibody 
WHO – World Health Organization 
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